<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hematol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Hematol Rep</journal-id><journal-id journal-id-type="publisher-id">hematolrep</journal-id><journal-title-group><journal-title>Hematology Reports</journal-title></journal-title-group><issn pub-type="ppub">2038-8322</issn><issn pub-type="epub">2038-8330</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407633</article-id><article-id pub-id-type="pmc">PMC12101282</article-id>
<article-id pub-id-type="doi">10.3390/hematolrep17030023</article-id><article-id pub-id-type="publisher-id">hematolrep-17-00023</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nappi</surname><given-names>Anna Giulia</given-names></name><xref rid="af1-hematolrep-17-00023" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4839-9033</contrib-id><name><surname>Dondi</surname><given-names>Francesco</given-names></name><xref rid="af2-hematolrep-17-00023" ref-type="aff">2</xref><xref rid="c1-hematolrep-17-00023" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Lazzarato</surname><given-names>Achille</given-names></name><xref rid="af3-hematolrep-17-00023" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Jonghi-Lavarini</surname><given-names>Lorenzo</given-names></name><xref rid="af4-hematolrep-17-00023" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Gorica</surname><given-names>Joana</given-names></name><xref rid="af5-hematolrep-17-00023" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>La Torre</surname><given-names>Flavia</given-names></name><xref rid="af6-hematolrep-17-00023" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6565-0686</contrib-id><name><surname>Santo</surname><given-names>Giulia</given-names></name><xref rid="af7-hematolrep-17-00023" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Miceli</surname><given-names>Alberto</given-names></name><xref rid="af8-hematolrep-17-00023" ref-type="aff">8</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cerchione</surname><given-names>Claudio</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Satoshi</surname><given-names>Yamasaki</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-hematolrep-17-00023"><label>1</label>Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari &#x0201c;Aldo Moro&#x0201d;, Piazza Giulio Cesare 11, 70124 Bari, Italy; <email>annagiulia.nappi@policlinico.ba.it</email></aff><aff id="af2-hematolrep-17-00023"><label>2</label>Nuclear Medicine, ASST Spedali Civili di Brescia and Universit&#x000e0; degli Studi di Brescia, 25123 Brescia, Italy</aff><aff id="af3-hematolrep-17-00023"><label>3</label>Nuclear Medicine Unit, ARNAS G. Brotzu, 09047 Cagliari, Italy; <email>achille.lazzarato@aob.com</email></aff><aff id="af4-hematolrep-17-00023"><label>4</label>Nuclear Medicine Department, IRRCS San Gerardo dei Tintori di Monza, 20900 Monza, Italy; <email>lorenzomaria.jonghi-lavarini@asst-cremona.it</email></aff><aff id="af5-hematolrep-17-00023"><label>5</label>Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, Italy; <email>joana.gorica@uniroma1.it</email></aff><aff id="af6-hematolrep-17-00023"><label>6</label>Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho Functional Imaging, University of Messina, 98125 Messina, Italy; <email>latorreflavia@gmail.com</email></aff><aff id="af7-hematolrep-17-00023"><label>7</label>Department of Experimental and Clinical Medicine, &#x0201c;Magna Graecia&#x0201d; University of Catanzaro, 88100 Catanzato, Italy; <email>giulia.santo@unicz.it</email></aff><aff id="af8-hematolrep-17-00023"><label>8</label>Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy; <email>alberto.miceli@ospedale.al.it</email></aff><author-notes><corresp id="c1-hematolrep-17-00023"><label>*</label>Correspondence: <email>francesco.dondi@unibs.it</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>23</elocation-id><history><date date-type="received"><day>03</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>14</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare and aggressive non-Hodgkin lymphoma (NHL), considered a specific entity with proper characteristics, therapies, and prognosis. First-line treatment is not unique, and subsequent strategies in case of disease persistence or relapse are the subject of debate and studies. In this scenario, [18F]FDG PET/CT plays a pivotal role both in characterizing the mediastinal mass, the main feature of PMLBCL, in staging, in restaging during therapy (interim PET), and at the end of treatment (EoT PET), to guide clinical management and give prognostic insights. The main issue with PMLBCL is distinguishing viable disease from residual fibrotic/inflammatory mass after therapy and, consequently, settling the next clinical strategy. Novel therapeutic approaches are ongoing and associated with the deepening of [18F]FDG PET/CT potentials as a principal tool in this context. In this review, we will explore PMLBCL from a Nuclear Medicine point of view to help clinicians in the management of these patients.</p></abstract><kwd-group><kwd>PMBCL</kwd><kwd>[18F]FDG</kwd><kwd>PET/CT</kwd><kwd>staging</kwd><kwd>restaging</kwd><kwd>diagnosis</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-hematolrep-17-00023"><title>1. Introduction</title><p>Primary mediastinal large B-cell lymphoma (PMLBCL) is a rare and aggressive subtype of non-Hodgkin lymphoma (NHL), originating in the mediastinum and characterized by a diffuse proliferation of medium to large B-cells in association with the presence of sclerosis. Previously classified as a diffuse large B-cell lymphoma (DLBCL) subtype, it is now recognized as a separate entity in the Lymphoid Malignancies WHO classification, in relation to its molecular, histological, and clinical characteristics [<xref rid="B1-hematolrep-17-00023" ref-type="bibr">1</xref>,<xref rid="B2-hematolrep-17-00023" ref-type="bibr">2</xref>]. PMLBCL constitutes 2&#x02013;3% of all NHL [<xref rid="B1-hematolrep-17-00023" ref-type="bibr">1</xref>,<xref rid="B3-hematolrep-17-00023" ref-type="bibr">3</xref>], and an annual incidence rate of 0.4 million has been derived in the US population from the Surveillance, Epidemiology, and End Results (SEER) database [<xref rid="B4-hematolrep-17-00023" ref-type="bibr">4</xref>], based on more than 400 patients diagnosed between 2000 and 2012, predominantly adolescents and young adults [<xref rid="B1-hematolrep-17-00023" ref-type="bibr">1</xref>]. PMLBCL mostly affects patients in the third and fourth decade of life, with a peak of incidence at 30&#x02013;39 years old, with a prevalence in females over males (ratio: 1.5), especially in white subjects. The five-year survival rate is generally 85%, while among specific populations (Asians, Hispanics, etc.) it is about 70%. Prognosis is lower for patients aged &#x02265; 60 years old, with a higher estimated risk (3.5 times greater) compared with young adults (18&#x02013;39 years). The late stage of disease, &#x0201c;other populations&#x0201d; groups, and socioeconomic status represent significant prognostic variables [<xref rid="B4-hematolrep-17-00023" ref-type="bibr">4</xref>]. No specific risk factors have been identified; however, genetic susceptibility, immune disorders, obesity, infectious conditions, occupational exposures, and socioeconomic status would appear to be involved in the increased incidence of disease observed in recent decades [<xref rid="B1-hematolrep-17-00023" ref-type="bibr">1</xref>,<xref rid="B5-hematolrep-17-00023" ref-type="bibr">5</xref>,<xref rid="B6-hematolrep-17-00023" ref-type="bibr">6</xref>,<xref rid="B7-hematolrep-17-00023" ref-type="bibr">7</xref>].</p><p>Morphologically, PMLBCL is defined by a diffuse proliferation of a large B-cell population within the thymus, with polymorphic nuclei and with clear or slightly basophilic cytoplasm, sclerosis, and a compartmentalization degree characterized by a fibrotic reaction with reticulin fiber thin strands surrounding neoplastic cell clusters. PMLBCL expresses B-cell antigens such as CD19, CD20, CD22, CD79a, and CD45, but they do not express surface immunoglobulins. CD30 is expressed in ~80% of cases and MAL (myelin and lymphocyte) in ~70%, differing from DLBCL and classical Hodgkin lymphoma (cHL) rare occurrence, while CD3, CD10, and CD21 are typically negative. Abnormal expression of MAL protein could be implicated in the lymphomagenesis process and neoplastic growth control [<xref rid="B8-hematolrep-17-00023" ref-type="bibr">8</xref>,<xref rid="B9-hematolrep-17-00023" ref-type="bibr">9</xref>]. Transcription factors that often turn out to be positive include PAX5, OCT2, BCL6, PU1, IRF4, and BOB1. PMLBCL pathobiology depends on molecular processes involving REL, JAK-STAT, PDL1, PDL2, and NFkB. Most common PMLBCL chromosomal abnormalities involve Cr 9p24 (with a JAK2 dysregulation and abnormal expression, with PDL1 and PDL2 amplification) and Cr 2p16 with REL proto-oncogene duplication encoding for NF-kB. Another mechanism involved is CIITA rearrangement, an MHC class II gene transactivator with a limitation of tumor cell interaction with T-cells. MHC-II downmodulation and PDL1 and PDL2 overexpression are functional to PMLBCL survival in the thymic microenvironment. JAK-STAT pathway deregulation is involved in oncogene activation, tumor suppressor gene inactivation, abnormal cell proliferation, tumor growth, and metastasis [<xref rid="B1-hematolrep-17-00023" ref-type="bibr">1</xref>,<xref rid="B10-hematolrep-17-00023" ref-type="bibr">10</xref>,<xref rid="B11-hematolrep-17-00023" ref-type="bibr">11</xref>,<xref rid="B12-hematolrep-17-00023" ref-type="bibr">12</xref>,<xref rid="B13-hematolrep-17-00023" ref-type="bibr">13</xref>].</p><p>In more than two-thirds of cases, PMLBCL appears with a large mass in the anterior mediastinum, often accompanied by local compressive symptoms such as dyspnea, cough (airway involvement and obstruction), and dysphagia. More than half of patients manifest with vena cava syndrome, which is characterized by the presence of thoracic and neck vein distension, facial and arm edema, and conjunctival swelling. One-third of patients present common B-symptoms (fever, night sweats, and weight loss) [<xref rid="B14-hematolrep-17-00023" ref-type="bibr">14</xref>]. Other clinical features that may occur include pleural/pericardial effusions and elevated serum lactate dehydrogenase (LDH). This mediastinal tumor can be frequently over 10 cm (bulky mass), infiltrating the lung, chest wall, pleura, and pericardium (70&#x02013;80%). The first manifestation can be both nodal and extranodal, but distant lymph node involvement is rare. Symptoms develop rapidly, and 80% of cases are diagnosed as stages I-II [<xref rid="B1-hematolrep-17-00023" ref-type="bibr">1</xref>]. However, a quarter of patients present with advanced-stage disease. PMLBCL recurrence often occurs in the extranodal district, with liver, gastrointestinal tract, kidney, adrenal gland, ovary, and central nervous system (leptomeningeal or intraparenchymal disease) involvement, with relatively uncommon bone marrow spread (1&#x02013;5% of cases) [<xref rid="B15-hematolrep-17-00023" ref-type="bibr">15</xref>].</p><p>PMLBCL diagnosis is based on clinical, morphological (large anterior mediastinal mass), and immunophenotypic criteria. Sclerosis may constitute the dominant histological feature of the microscopic picture with high heterogeneity in tumor different areas. Diagnostic tissue samples should be, therefore, obtained by tumor mass percutaneous needle biopsy, mediastinoscopy, or by anterior mediastinotomy, or mini-thoracotomy [<xref rid="B16-hematolrep-17-00023" ref-type="bibr">16</xref>]. The staging work-up is based on the Ann Arbor Staging System for Hodgkin and non-Hodgkin lymphoma. Diagnosis and staging are determined by history, physical examination, imaging studies, laboratory tests, initial biopsy, immunohistochemistry, and bone marrow aspirate [<xref rid="B17-hematolrep-17-00023" ref-type="bibr">17</xref>]. The main imaging methods for PMLBCL diagnosis are represented by Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET). A mediastinal mass, a deviation of the tracheal axis with or without caliber narrowing, pleural/pericardial effusions, and unilateral hemidiaphragm elevation can be observed even on initial evaluation using X-ray imaging. However, CT is commonly used as a first-line imaging modality for detecting tumor extension. Namely, neck and chest CT scans allow us to identify the presence of posterior mediastinum or subcarinal region tumor masses, which represent less frequent PMLBCL localizations, as well as the superior vena cava syndrome with mediastinal vessel compression and venous thrombosis. Mediastinal masses usually show low-attenuation features on CT, including necrosis, cystic degeneration, and bleeding. Despite its significant role in staging, CT is less useful in recognizing residual lesions and monitoring treatment efficacy because of its limited role in discriminating between residual disease or post-treatment fibrotic reaction [<xref rid="B18-hematolrep-17-00023" ref-type="bibr">18</xref>]. MRI can play a role in the definition of the intrathoracic extension of the disease, in assessing large vessels, as well as cardiac and chest wall involvement. Similarly, after treatment, but with scarce prognostic value, the residual tumor often shows a heterogeneous signal intensity on T2-weighted images, while high signal intensity on T2 or low signal intensity on T1 can be related to inflammation, necrosis, or active lymphoma. On the contrary, homogeneous hypointensity can be appreciated in fibrotic masses [<xref rid="B18-hematolrep-17-00023" ref-type="bibr">18</xref>,<xref rid="B19-hematolrep-17-00023" ref-type="bibr">19</xref>,<xref rid="B20-hematolrep-17-00023" ref-type="bibr">20</xref>,<xref rid="B21-hematolrep-17-00023" ref-type="bibr">21</xref>,<xref rid="B22-hematolrep-17-00023" ref-type="bibr">22</xref>,<xref rid="B23-hematolrep-17-00023" ref-type="bibr">23</xref>,<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>,<xref rid="B25-hematolrep-17-00023" ref-type="bibr">25</xref>].</p><p>[18F]Fluorodesoxyglucose (FDG) PET/CT is a well-known diagnostic tool commonly used for FDG-avid HL and NHL. This imaging method is useful for characterizing lymphadenopathies or masses, for guiding biopsy, and for detecting extra-mediastinal tissues such as bone marrow involvement. Moreover, also in PMBCL, [18F]FDG PET/CT plays a major role in staging, and afterward, in monitoring response to treatments. Commonly, Revised Lugano classification and International Harmonization Project in Lymphoma, using a five-point visual scale, commonly known as the Deauville score (DS), are used. The DS allows us to compare the most intense uptake in a site of initial disease with the tracer uptake in the liver and in the mediastinal blood pool to define metabolic response as complete, partial, or progressive disease after treatments (for more details, see <xref rid="app1-hematolrep-17-00023" ref-type="app">Supplementary Materials</xref>).</p><sec><title>Treatment Options for PMLBCL</title><p>First-line treatment choice plays an essential role in PMLBCL because of the limited efficacy of salvage therapy of recurrence/progressive disease. The major open issues regarding PMLBCL treatment deal with (i) which type of chemotherapy regimen to adopt as the first line (choice of a first- or third-generation chemotherapy protocol, including or not including Rituximab); (ii) the evaluation of high-dose protocol benefits; and (iii) the role of consolidation radiotherapy (RT) on the mediastinum, maintaining a balance between the fraction of cure (as high as possible) and the reduction in long-term morbidity (as much as possible) [<xref rid="B3-hematolrep-17-00023" ref-type="bibr">3</xref>,<xref rid="B26-hematolrep-17-00023" ref-type="bibr">26</xref>].</p><p>Generally, a higher rate of refractory/relapsed disease is observed in patients with PMLBCL compared to DLBCL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) protocol [<xref rid="B26-hematolrep-17-00023" ref-type="bibr">26</xref>]. In the pre-Rituximab era, PMLBCL patients showed higher response rates (with longer PFS and OS), when treated with third-generation chemotherapy (such as etoposide/methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin&#x02014;MACOP-B/VACOP-B) compared to CHOP protocol, as shown by several European studies [<xref rid="B27-hematolrep-17-00023" ref-type="bibr">27</xref>,<xref rid="B28-hematolrep-17-00023" ref-type="bibr">28</xref>]. In 2006, after the approval of Rituximab by the FDA, an improvement in outcomes in all DLBCL subtypes was shown by using the combined protocol (R-CHOP, DA-EPOCH-R, R-VACOP-B). After first-line treatment, consolidation RT can improve response rate and long-term survival in subjects with residual or recurrent mediastinal disease in this setting, despite possible long-term harmful effects due to radiation exposure, especially given the young age of these patients. Long-term harmful effects include the increased risk of second malignancy (particularly, breast cancer) and cardio-pulmonary damage, such as accelerated coronary artery disease [<xref rid="B29-hematolrep-17-00023" ref-type="bibr">29</xref>]. Some studies which compared R-CHOP therapeutic protocol plus RT vs. DA-EPOCH-R regimen, without RT, showed similar efficacy between the two different therapeutic strategies. However, whether high-dose chemotherapy can replace RT remains to be addressed [<xref rid="B30-hematolrep-17-00023" ref-type="bibr">30</xref>], and generally, the role of RT in PMLBCL is, anyway, a matter of debate. The reliability of consolidation use is undeniable, especially in PMLBCL with residual disease (DS &#x0003e; 3), possibly converting a PMR into CMR after chemotherapy [<xref rid="B27-hematolrep-17-00023" ref-type="bibr">27</xref>]. Conversely, the use of RT after chemotherapy in patients with CMR remains uncertain and needs further study. Currently, the initial treatment of PMLBCL has no universally accepted standard of care or regimen.</p><p>As second-line treatment with R- dexamethasone, cytarabine and cisplatin/oxaliplatin (DHAP)/(DHAOX) is used for four cycles, plus carmustine/fotemustine, etoposide, cytarabine, and melphalan (BEAM/FEAM), followed by autologous stem cell transplant (ASCT) [<xref rid="B31-hematolrep-17-00023" ref-type="bibr">31</xref>]. New therapeutic approaches are now under investigation and will be discussed in this review.</p><p>Further, histological confirmation before embarking on further aggressive salvage chemotherapy could be considered in some cases [<xref rid="B32-hematolrep-17-00023" ref-type="bibr">32</xref>,<xref rid="B33-hematolrep-17-00023" ref-type="bibr">33</xref>,<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>].</p><p>This comprehensive review aims to demonstrate and summarize the role of [18F]FDG PET/CT in every step of patient management, from staging to treatment response evaluation, in order to guide decision-making regarding the best personalized treatment option, and to explore the role of [18F]FDG PET/CT as a prognostic marker for patients affected by PMLBCL. Finally, an overview of the question under study/future perspectives in the evolving field of PMLBCL will be given.</p></sec></sec><sec id="sec2-hematolrep-17-00023"><title>2. [18F]FDG PET/CT in PMLBCL</title><sec id="sec2dot1-hematolrep-17-00023"><title>2.1. Diagnosis</title><p>Even if histological results are mandatory to confirm diagnosis, there is increasing interest in the potential role of [18F]FDG PET/CT in characterizing mediastinal masses before biopsy to guide the clinician in the diagnostic process.</p><p>One of the main concerns, in fact, is the ability of [18F]FDG PET/CT to differentiate PMBCL from other mediastinal entities. In this scenario, some studies aimed to assess the reliability of different PET parameters to distinguish PMBCL from thymic epithelial tumors (TETs) (<xref rid="hematolrep-17-00023-t001" ref-type="table">Table 1</xref>). In a 2020 study, Zhu and colleagues, in a cohort of 136 patients pathologically diagnosed with TETs or PMBCL, showed that all metabolic parameters extracted from baseline [18F]FDG PET/CT significantly differed between groups; specifically, patients with lymphomas were younger and had higher SUVmean, SUVmax, TLG, and MTV values than patients with TETs [<xref rid="B35-hematolrep-17-00023" ref-type="bibr">35</xref>].</p><p>Recently, Yan et al. confirmed these data in a similar retrospective study with 304 patients, finding that lymphomas were significantly associated with younger patient age, higher LDH level, larger tumor size, and higher SUVmax compared to TETs (<italic toggle="yes">p</italic> &#x0003c; 0.001). Moreover, the accuracy of age, LDH, tumor size, and SUVmax in predicting lymphoma was 84.8%, 67.8%, 85.2%, and 78.3%, respectively. The combination of the four above parameters could improve the predictive accuracy to 89.1% [<xref rid="B36-hematolrep-17-00023" ref-type="bibr">36</xref>].</p><p>An interesting work regarding the use of baseline [18F]FDG PET/CT in PMBCL was performed by Alkhawtani et al. [<xref rid="B37-hematolrep-17-00023" ref-type="bibr">37</xref>]. They included in their study a total of 56 patients (42 with mediastinal HL and 14 with PMBCL) to evaluate the ability of PET/CT metrics to differentiate HL from PMBCL, which can both present with an anterior mediastinal tumor mass. Lesion-to-liver SUVmax ratio and lesion-to-liver SUVpeak ratio were significantly higher in PMBCL than in HL (<italic toggle="yes">p</italic>-value &#x0003c; 0.001). Furthermore, higher lactate dehydrogenase (LDH) value, larger tumor diameter, and more frequent necrosis were all elements that helped to distinguish PMBCL from HL, reflecting the more aggressive tumor biology of the former compared to the latter. AUC for lesion-to-liver SUVmax ratio and lesion-to-liver SUVpeak ratio were 0.875 and 0.874, with optimal cut-off values of 7.12 (94.9% sensitivity and 64.3% specificity) and 11.45 (97.4% sensitivity and 64.3% specificity), respectively [<xref rid="B37-hematolrep-17-00023" ref-type="bibr">37</xref>].</p><p>To differentiate the most common subtype of bulky mediastinal lymphomas, Abenavoli et al. enrolled 117 patients, of which 80 had HL, 29 had PMBCL, and 8 had gray zone lymphoma (GZL), and combined radiomics with metabolic texture analysis (TA) to quantitatively estimate intratumor heterogeneity. The authors found that SUVmax and TLG showed the highest values in the PMBCL group, and MTV was higher in PMBCL and GZL compared to the HL group, as expected in line with the most aggressive biological behavior of PMBCL. In addition, metabolic heterogeneity is also a remarkable feature of malignancy, and texture analysis showed a higher value of heterogeneity and entropy in PMBCL than in the HL group. Referring to the GLZM matrix, the Zone-Length Non-Uniformity, which measures the variability of the intensity values of the gray-level in the image, showed higher values in PMBCL. Machine learning (ML) algorithms combined with radiomics could be a robust histological-based tool in discriminating lymphoma subtypes [<xref rid="B38-hematolrep-17-00023" ref-type="bibr">38</xref>].</p></sec><sec id="sec2dot2-hematolrep-17-00023"><title>2.2. Staging</title><p>It has generally been reported that [18F]FDG PET/CT performed before any treatment in lymphoma can give fundamental prognostic information, and PMBCL does not make any exception [<xref rid="B39-hematolrep-17-00023" ref-type="bibr">39</xref>]. Staging [18F]FDG PET/CT could identify the minority of PMBCL patients who experienced chemorefractory disease associated with poor outcomes. The first to evaluate the role of staging [18F]FDG PET/CT in PMBCL patients were Ceriani et al. [<xref rid="B40-hematolrep-17-00023" ref-type="bibr">40</xref>], based on the International Extranodal Lymphoma Study Group (IELSG) 26 study [<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>]. All the 103 patients included had undergone subsequent treatment with rituximab plus anthracycline-containing regimens (R-CHOP or R-CHOP like, R-VACOP-B or R-MACOP-B), and 93 of them had also undergone consolidation RT on the mediastinum. A significantly shorter PFS and overall survival (OS) were associated with an increase in MTV (PFS analysis: HR 1.36; 95%CI: 1.16&#x02013;1.61, <italic toggle="yes">p</italic> &#x0003c; 0.001; OS analysis: HR, 1.39, 95%CI: 1.08&#x02013;1.77, <italic toggle="yes">p</italic> = 0.009) and TLG (PFS analysis: HR 1.40; 95%CI: 1.25&#x02013;1.58, <italic toggle="yes">p</italic> &#x0003c; 0.001, OS analysis: HR 1.47, 95%CI: 1.22&#x02013;1.76, <italic toggle="yes">p</italic> &#x0003c; 0.001), but not with an increase in SUVmax. Only TLG demonstrated statistical significance for both OS (<italic toggle="yes">p</italic> &#x0003c; 0.001) and PFS (<italic toggle="yes">p</italic> &#x0003c; 0.001) in multivariate analysis. Long-term outcomes were significantly better for subjects with low TLG, and this parameter showed an extremely high negative predictive power, since no deaths and only one relapse were reported among patients with low baseline TLG values. TLG was confirmed as the strongest independent predictor of PMBCL outcomes for both OS (<italic toggle="yes">p</italic>-value &#x0003c; 0.0027) and PFS (<italic toggle="yes">p</italic>-value &#x0003c; 0.0001), to risk-stratify patients that could benefit from treatment intensification [<xref rid="B40-hematolrep-17-00023" ref-type="bibr">40</xref>].</p><p>This evidence, which emerged from an IELSG-26 study for patients treated with non-EPOCH-based treatment, was confirmed by Pinnix et al., who retrospectively enrolled 65 patients with newly diagnosed PMBCL and who were treated with a DA-EPOCH regimen [<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>]. Of baseline PET/CT semiquantitative parameters (SUVmax, MTV, and TLG), the area under the curve (AUC) was significant for TLG (0.756; <italic toggle="yes">p</italic>-value 0.006), and the cut-off value of 3941.4 g proved optimal for classifying patients at low and high risk of progression, with sensitivity and specificity of 83% and 70%, respectively. Machine learning-derived thresholds for both MTV and TLG showed promising results in predicting disease progression. Subsequent multivariate analysis confirmed TLG as the only reliable prognosticator (HR, 7.879; <italic toggle="yes">p</italic>-value 0.049). Finally, if elevated baseline TLG was combined with an end-of-treatment Deauville score of 4 to 5, the sensitivity improved to 83% in predicting disease progression.</p><p>Similarly, Liu et al. confirmed the powerful prognostic role of baseline MTV and TLG in predicting worse PFS in 26 PMBCL patients that received DA-R-EPOCH and consolidation RT. The authors reported cut-off values of 500 for MTV (<italic toggle="yes">p</italic> = 0.002) and 2500 g for TLG (<italic toggle="yes">p</italic> = 0.023), respectively, correlated with worse PFS [<xref rid="B42-hematolrep-17-00023" ref-type="bibr">42</xref>].</p><p>However, Zhou et al., in their retrospective study enrolling 166 patients treated with different chemotherapy regimens (R-CHOP, R-EPOCH, and R-HCVAD), focused on the prognostic value of different clinical&#x02013;genetical features, and considered SUVmax as the only PET parameter. The authors showed that patients with SUVmax &#x0003e; 11.6 at diagnosis had the worst OS (<italic toggle="yes">p</italic>-value 0.021), and most of them were treated with the R-EPOCH regimen [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>].</p><p>Going beyond PET semi-quantitative parameters, Ceriani et al. [<xref rid="B44-hematolrep-17-00023" ref-type="bibr">44</xref>,<xref rid="B45-hematolrep-17-00023" ref-type="bibr">45</xref>] showed interest in studying tumor heterogeneity, a complex phenomenon that reflects variable phenotype profiles, genome instability, and epigenetic variation that has been associated with chemoresistance and treatment failure. [18F]FDG PET/CT may show metabolic intratumoral heterogeneity (MH), previously associated with poor prognosis in solid tumors [<xref rid="B46-hematolrep-17-00023" ref-type="bibr">46</xref>,<xref rid="B47-hematolrep-17-00023" ref-type="bibr">47</xref>,<xref rid="B48-hematolrep-17-00023" ref-type="bibr">48</xref>,<xref rid="B49-hematolrep-17-00023" ref-type="bibr">49</xref>]. The authors evaluated the prognostic role of the MH of baseline [18F]FDG PET/CT images in the known IELSG-26 study cohort. MH was defined as the percentage of tumor volume, with SUV above a certain threshold, plotted against threshold values varying from 25% to 100% of SUVmax, excluding necrotic areas with very low or absent FDG uptake [<xref rid="B44-hematolrep-17-00023" ref-type="bibr">44</xref>]. The AUC was a quantitative index of tracer uptake heterogeneity, with lower values corresponding to increased heterogeneity [<xref rid="B45-hematolrep-17-00023" ref-type="bibr">45</xref>]. MH distribution was also evaluated by estimating the coefficient of variation in the intratumoral FDG uptake, calculated as the standard deviation of the SUV divided by the SUVmean of the segmented lesion. MH values did not show a significant relationship with other baseline PET semiquantitative parameters (SUVmax, MTV, TLG). The receiver-operating characteristic (ROC) analysis of AUC identified an optimal cut-off of 0.45 to discriminate patients with disease progression or relapse, with a sensitivity of 69% (95%CI: 39&#x02013;91%) and specificity of 72% (95%CI: 62&#x02013;81%). In this setting, subjects with progression or relapse had significantly higher MH than those with complete remission (<italic toggle="yes">p</italic> = 0.012). PFS was significantly longer for patients with low MH (<italic toggle="yes">p</italic> &#x0003c; 0.0001). Elevated MH (HR 12.8, 95%CI: 3.3&#x02013;49.9, <italic toggle="yes">p</italic> &#x0003c; 0.001) and elevated TLG (HR 46.5, 95%CI: 5.8&#x02013;373.8, <italic toggle="yes">p</italic> &#x0003c; 0.001) were found to be independent prognosticators for PFS, so they were combined in a prognostic model for PFS: patients with both high TLG and high MH had poorer outcomes (HR: 31.2, 95%CI: 9.9&#x02013;97.8, <italic toggle="yes">p</italic> &#x0003c; 0.001). MH may be an additional biomarker in PMBCL, suggesting that combining it with TLG in a prognostic model may improve PPV and may adequately screen high-risk patients needed for more intensive treatment [<xref rid="B45-hematolrep-17-00023" ref-type="bibr">45</xref>].</p><p>Due to the prognostic importance of volumetric PET parameters, but the low reproducibility of the results, the same study group investigated the most reliable method and threshold to accurately estimate MTV, evaluating the accuracy in predicting PFS and OS in the IELSG-26 study cohort [<xref rid="B50-hematolrep-17-00023" ref-type="bibr">50</xref>]. In this study, the authors compared methods for metabolic volume segmentation by applying three thresholds (FT25% = 25%, FT41% = 41% of the SUVmax, and FT2.5 = an absolute SUV value of 2.5) and by means of a region growing (RG) algorithm [<xref rid="B48-hematolrep-17-00023" ref-type="bibr">48</xref>]. In PMBCL patients, characterized by a dominant bulky mediastinal lesion, the FT25% provided the most accurate estimation of the actual volume. Patients with low MTV had significantly longer PFS and OS, regardless of the method used, but the optimal cut-offs for MTV to predict PFS and OS were method-related. The four methods predicted disease progression with similar NPV (95&#x02013;98%), but the highest PPV (45%) was for FT25%, which provided the best model to identify patients with the worse outcome. These results confirmed the relationship between the most accurate estimation of the actual volume of the lesions and the best risk classification [<xref rid="B50-hematolrep-17-00023" ref-type="bibr">50</xref>].</p><p>In conclusion, volumetric parameters (MTV and TLG), particularly TLG, could be considered powerful prognostic biomarkers to predict PFS and OS, as shown by all reported studies&#x02019; results, and the combination of these parameters with MH could improve the risk-adapted strategies in PMBCL patients. <xref rid="hematolrep-17-00023-t002" ref-type="table">Table 2</xref> summarizes the characteristics of studies included in this section.</p></sec><sec id="sec2dot3-hematolrep-17-00023"><title>2.3. Early Treatment Response Assessment&#x02014;iPET</title><p>The use of interim [18F]FDG PET/CT (iPET) has been widely proven to have an excellent NPV and accurate prognostic insights, especially in HL (with the subsequent creation of multiple assessment scales, e.g., DS) [<xref rid="B51-hematolrep-17-00023" ref-type="bibr">51</xref>,<xref rid="B52-hematolrep-17-00023" ref-type="bibr">52</xref>,<xref rid="B53-hematolrep-17-00023" ref-type="bibr">53</xref>,<xref rid="B54-hematolrep-17-00023" ref-type="bibr">54</xref>] as well as in DLBCL [<xref rid="B55-hematolrep-17-00023" ref-type="bibr">55</xref>,<xref rid="B56-hematolrep-17-00023" ref-type="bibr">56</xref>,<xref rid="B57-hematolrep-17-00023" ref-type="bibr">57</xref>,<xref rid="B58-hematolrep-17-00023" ref-type="bibr">58</xref>,<xref rid="B59-hematolrep-17-00023" ref-type="bibr">59</xref>]. Nevertheless, some controversy about the role of iPET remains, for example, in advanced-stage disease patients [<xref rid="B60-hematolrep-17-00023" ref-type="bibr">60</xref>,<xref rid="B61-hematolrep-17-00023" ref-type="bibr">61</xref>]. This issue is also debated in PMBCL patients, in which the prognostic significance of iPET remains unclear due to the scarcity of available data, the relative rarity of the PMBCL subtype, and the small sample size enrolled in the few studies currently available, whose data should be used with caution due to a lack of a standardized method of interpretation of iPET results in this context (mainly change in SUV value&#x02014;&#x00394;SUV, or a 5-point scale DS) [<xref rid="B62-hematolrep-17-00023" ref-type="bibr">62</xref>].</p><p>In 2014, Avigdor and colleagues retrospectively analyzed the value of iPET in 30 PMBCL consecutive patients receiving Rituximab-containing chemotherapy and who underwent iPET before starting the seventh cycle of R-VACOP-B or after the third cycle of R-CHOP21. On the basis of visual assessment, a negative iPET was able to efficiently predict excellent outcome, since a negative iPET was reported in 16/30 subjects (50%) who remained in complete response at the end of therapy, with a single exception. Furthermore, a positive iPET identified subjects with poor prognosis and, in particular, 14/30 patients (47%) had positive findings: nine of them had CMR, one had PMD, and four had PMR at the end of treatment. The 5-PFS was 94% (95%CI 62&#x02013;99%) and 57% (95%CI 28&#x02013;78%) for negative and positive iPET, respectively (<italic toggle="yes">p</italic> = 0.015). Overall, 70% of the cohort had the outcome predicted by iPET, which confirmed a high NPV (94% and 100% for R-VACOP-B and 86% for R-CHOP) but a poor PPV (43% and 30% for R-VACOP-B and 75% for R-CHOP) [<xref rid="B63-hematolrep-17-00023" ref-type="bibr">63</xref>]. Interestingly, this low value of PPV could be predicted by persistent inflammatory response and fibrosis, persisting even after a successful treatment regimen, therefore mimicking the presence of residual neoplastic mediastinal mass [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>,<xref rid="B64-hematolrep-17-00023" ref-type="bibr">64</xref>]. Based on the visual assessment, negative iPET efficiently predicted an excellent outcome; indeed, iPET was negative in 16/30 patients (53%), and all remained in complete response at the end of therapy, with only one relapse. Positive iPET partly identifies patients with poor prognosis; indeed, iPET was positive in 14/30 patients (47%) and 9/14 had CMR, while 4/14 had PMR and 1/14 had PMD at the end of therapy. Further, 5-year PFS was 94% (95%CI 62&#x02013;99%) for negative iPET and 57% (95%CI 28&#x02013;78%) for positive iPET (<italic toggle="yes">p</italic> = 0.015). Overall, iPET predicted treatment outcome in 70% of the patients, confirming a high NPV (94% and 100% for R-VACOP-B and 86% for R-CHOP) but a PPV of only 43% (30 for R-VACOP-B and 75% for R-CHOP) [<xref rid="B63-hematolrep-17-00023" ref-type="bibr">63</xref>]. The low PPV could be explained by the inflammatory fibrosis that persisted even after successful treatment, mimicking residual mediastinal mass [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>,<xref rid="B64-hematolrep-17-00023" ref-type="bibr">64</xref>].</p><p>Cheah et al.&#x02019;s study emphasized the high NPV (87&#x02013;88%) of iPET, irrespective of the method of interpretation, while positive iPET was not predictive of inferior PFS, confirming the low PPV for relapse (12.5&#x02013;15%) [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>].</p><p>In a retrospective study, Lazarovici et al. directly compared positive iPET results with histological analysis consisting in a surgical debulking of the residual mediastinal mass or a CT-guided needle biopsy. iPET was performed after the fourth cycle of immunochemotherapy in 36 PMBCL treated by combining an anti-CD20 monoclonal antibody with CHOP or CHOP-like chemotherapy. Applying visual analysis subsequently reassessed using DS, iPET was positive in 17 (47%) patients, of which 3 (17%) has DS &#x02264; 3 and 14 (82%) had DS 4, and was negative in 19 (53%) patients, of which 14 patients (74%) had DS &#x02264; 3 and 5 (26%) had DS 4. All positive groups underwent histological restaging, which revealed inflammatory necrosis and fibrosis in 15/17 patients, silicosis in 1 patient, and persistent disease in only 1 patient. Given the frequent iPET positive results in mediastinum, the authors concluded that iPET may be considered a false positive in 94.1% of cases with a very low PPV (16.6%), meaning it does not reflect the persistence of active disease in the vast majority of PMBCL cases, regardless of using the International Harmonization Project (IHP) criteria, &#x00394;SUV, or DS [<xref rid="B62-hematolrep-17-00023" ref-type="bibr">62</xref>]. However, in a comment published by Qin et al., the authors underlined the absence of interim DS 5 patients in the aforementioned cohort. Thus, they investigated the role of iPET in 49 PMBCL patients (44.9% received R-CHOP, and 55.1% DA-EPOCH-R). Subjects with interim DS 5, of which 5/10 patients also had histological confirmation, had poor treatment response and shorter survival; indeed, the overall response rate (ORR) was 30.0% (3/10), a value significantly lower than in those patients with interim DS 1&#x02013;3 (96.8%, <italic toggle="yes">p</italic> &#x0003c; 0.001) or DS 4 (87.5%, <italic toggle="yes">p</italic> = 0.025), respectively. Moreover, the 2-year PFS value was 20% for interim DS 5, which was significantly shorter than interim DS 1&#x02013;3 (93.4%, <italic toggle="yes">p</italic> &#x0003c; 0.001) or DS 4 (69.3%, <italic toggle="yes">p</italic> = 0.012); OS was 67.7% for interim DS 5, shorter than interim DS 1&#x02013;3 (95.8%, <italic toggle="yes">p</italic> = 0.003). No differences in ORR, PFS, or OS were observed between patients with interim DS 1&#x02013;3 and DS 4, so these were categorized as DS 1&#x02013;4 with a good outcome; indeed, none of them experienced disease progression or relapse during follow-up. These results are more encouraging regarding the role of iPET in effectively identifying PMBCL patients with poor clinical outcomes, based on the high PPV of interim DS 5, that should be candidates for further treatment [<xref rid="B64-hematolrep-17-00023" ref-type="bibr">64</xref>].</p><p>Therefore, the prognostic significance of iPET in PMBCL is still debatable and remains, moreover, an open issue, because of the inconsistency of results obtained in clinical studies and reported in the literature. Whilst the NPV is still excellent, the relatively low PPV and specificity [<xref rid="B62-hematolrep-17-00023" ref-type="bibr">62</xref>,<xref rid="B63-hematolrep-17-00023" ref-type="bibr">63</xref>] and high false positive results were frequently related to benign lymphoid reactive or follicular hyperplasia, sarcoid-like granulomatosis, thymic hyperplasia or rebound, and fibrosis [<xref rid="B65-hematolrep-17-00023" ref-type="bibr">65</xref>]. To explain such a phenomenon, some authors speculate that the overexpression of the glucose transporter GLUT1 could play a role in the persistent mediastinal [18F]FDG avidity [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>,<xref rid="B66-hematolrep-17-00023" ref-type="bibr">66</xref>], and that the addition of rituximab to chemotherapy could produce an inflammatory response that could cause increased [18F]FDG uptake [<xref rid="B67-hematolrep-17-00023" ref-type="bibr">67</xref>]. Since it is commonly accepted that most positive iPET results correspond to an actual residual inflammatory fibrosis and not to a viable tumor, it is a widespread opinion that good outcomes can still be achieved with chemotherapy even in most patients with a positive iPET that thus have frequently no impact on clinical decision-making [<xref rid="B62-hematolrep-17-00023" ref-type="bibr">62</xref>].</p><p>To improve the specificity of iPET, numerous studies state that a histological confirmation of the residual mass should be mandatory, and, therefore, therapeutic changes for PMBCL should not be made solely based on iPET results. Larger multicentric collaborations in randomized clinical study trials with large multicenter collaborations are still needed to understand the natural evolution of PET results in PMBCL across different treatment time-points, to validate the prognostic value of iPET and to achieve a common agreement on the most reliable and powerful predictor, the iPET interpretation method [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>,<xref rid="B62-hematolrep-17-00023" ref-type="bibr">62</xref>,<xref rid="B68-hematolrep-17-00023" ref-type="bibr">68</xref>,<xref rid="B69-hematolrep-17-00023" ref-type="bibr">69</xref>]. Characteristics of included studies are summarized in <xref rid="hematolrep-17-00023-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec2dot4-hematolrep-17-00023"><title>2.4. End-of-Treatment Response Assessment&#x02014;EoT PET</title><p>Currently, [18F]FDG PET/CT is incorporated into the therapeutic decision-making for ensuring tailored chemo- and radiotherapy strategies in PMBCL patients [<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>]. To overcome the PMBCL tendency to recur, mediastinal RT is incorporated in different therapeutic strategies, since it is capable of converting partial to complete response, and of consolidating disease control in case of complete response [<xref rid="B70-hematolrep-17-00023" ref-type="bibr">70</xref>]. However, various authors sustained that PET-based response after different therapeutic regimens should be considered as a reference, limiting RT indication eventually to PET-persistent disease patients [<xref rid="B71-hematolrep-17-00023" ref-type="bibr">71</xref>,<xref rid="B72-hematolrep-17-00023" ref-type="bibr">72</xref>,<xref rid="B73-hematolrep-17-00023" ref-type="bibr">73</xref>] (<xref rid="hematolrep-17-00023-t004" ref-type="table">Table 4</xref>).</p><p>In several studies with different immunochemotherapy protocols, the authors shared a strategy of administering RT to PET-positive patients, while it was omitted for clearly PET-negative patients or based on the decision of a treating physician [<xref rid="B74-hematolrep-17-00023" ref-type="bibr">74</xref>,<xref rid="B75-hematolrep-17-00023" ref-type="bibr">75</xref>]. Similarly, in a recent publication by Held et al., in a subgroups analysis of the UNFOLDER Trial, 131 PMBCL patients were randomized in a 2 &#x000d7; 2 factorial design to R-CHOp-21 vs. R-CHOP-14, and additive RT vs. observation, demonstrating a significant superior 3-year event-free survival after RT, without impact on PFS and OS. The authors concluded that RT seemed not to be required for all patients, and PET should be used to guide clinical decisions. RT might be spared for patients achieving a PET complete response after an R-CHOP-based regimen, while poor responders with PET-positive residual mass (DS 4&#x02013;5) might benefit from RT [<xref rid="B76-hematolrep-17-00023" ref-type="bibr">76</xref>].</p><p>This PET-adapted strategy significantly reduces (&#x02212;64%) the number of patients who received consolidative RT without affecting outcome [<xref rid="B77-hematolrep-17-00023" ref-type="bibr">77</xref>]. However, it is not fully clarified whether RT might be avoided solely based on a negative PET scan [<xref rid="B78-hematolrep-17-00023" ref-type="bibr">78</xref>]. A different PET-based strategy was adopted by Shemmari et al. that administered consolidation RT in PET-negative patients after R-CHOP, while PET-positive patients were treated with salvage chemotherapy followed by ASCT [<xref rid="B31-hematolrep-17-00023" ref-type="bibr">31</xref>].</p><p>Finding true positive and true negative PET, however, is the crucial issue in PMBCL scenarios, with respect to other lymphomas.</p><p>In this context, [18F]FDG PET/CT surely helps to detect small mediastinal residual lesions important for better RT planning, even if a high incidence of false positive findings is reported after rituximab-base regimens, as mentioned before. A longer time interval from the last treatment cycle and the EoT PET might reduce the false positive rate, but increase the risk of missing the opportunity to cure persistent disease with RT. Although invasive, a new biopsy of remnant tissue for a histological confirmation should be discussed and considered in some cases before starting subsequent aggressive salvage chemotherapy too quickly [<xref rid="B32-hematolrep-17-00023" ref-type="bibr">32</xref>,<xref rid="B33-hematolrep-17-00023" ref-type="bibr">33</xref>,<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>].</p><p>The use of EoT PET imaging to predict patient outcomes is of considerable interest in PMBCL patients, especially thanks to the application of response assessment criteria useful for standardizing physician interpretation. PET response was initially established according to the IHP criteria, based on visual analysis alone [<xref rid="B79-hematolrep-17-00023" ref-type="bibr">79</xref>]. In recent years, response assessment was preferentially based on the internationally validated DS [<xref rid="B80-hematolrep-17-00023" ref-type="bibr">80</xref>,<xref rid="B81-hematolrep-17-00023" ref-type="bibr">81</xref>]. This scale quantifies uptake in residual tumor masses to better differentiate active lymphoma from fibrotic mass [<xref rid="B33-hematolrep-17-00023" ref-type="bibr">33</xref>]. Based on these criteria, the aforementioned prospective IELSG-26 study provided the first validation of Lugano classification in defining treatment response in a PMBCL cohort, to be used for patient risk stratification and treatment adaptation. Unlike other forms of [18F]FDG-avid lymphoma, a DS-3 category was considered borderline, depending on the timing of evaluation and the clinical context [<xref rid="B82-hematolrep-17-00023" ref-type="bibr">82</xref>]. In the IELSG-26 study, a worse PFS (99% vs. 68%) and OS (100% vs. 83%) were observed for DS 4&#x02013;5 patients compared to DS 1&#x02013;3 [<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>,<xref rid="B80-hematolrep-17-00023" ref-type="bibr">80</xref>]; therefore, patients with EoT DS &#x0003e; 3 should be considered at higher risk of relapse and candidates for further treatments [<xref rid="B72-hematolrep-17-00023" ref-type="bibr">72</xref>,<xref rid="B83-hematolrep-17-00023" ref-type="bibr">83</xref>,<xref rid="B84-hematolrep-17-00023" ref-type="bibr">84</xref>]. Different authors emphasized the excellent NVP (95&#x02013;100%) of EoT PET negative scan (DS 1&#x02013;3) [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>,<xref rid="B85-hematolrep-17-00023" ref-type="bibr">85</xref>]. From these premises, the cut-off point for PET positivity was moved from the mediastinal blood pool uptake (DS 3) to liver uptake (DS 4), to increase PPV (from 18% to 32%), and to ensure a clearer distinction between risk subgroups in terms of PFS and OS [<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>,<xref rid="B31-hematolrep-17-00023" ref-type="bibr">31</xref>,<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>,<xref rid="B80-hematolrep-17-00023" ref-type="bibr">80</xref>,<xref rid="B83-hematolrep-17-00023" ref-type="bibr">83</xref>].</p><p>Although a better PPV was observed for the EoT PET compared to iPET, showing a reduction in the DS from interim to EoT [<xref rid="B78-hematolrep-17-00023" ref-type="bibr">78</xref>], the EoT PET PPV result was still limited, given that post-immunochemotherapy inflammation commonly occurred. In a subanalysis of the IELSG-26 trial focusing on the irradiation response assessment, persistent [18F]FDG uptake after RT seems likely to reflect a post-treatment inflammatory reaction rather than an active disease, not necessarily requiring salvage therapy, confirming the unsatisfactory specificity for PET-positive scan (DS &#x02265; 4) even after RT [<xref rid="B84-hematolrep-17-00023" ref-type="bibr">84</xref>]. Probably, Deauville criteria have some limitations in correctly discriminating minimal refractory disease from inflammatory reaction. In contrast with these results, the IELSG-37 trial suggested a prudential cut-off of DS 3, considering those with DS 3 as PET-positive patients, but with uncertainty on the appropriate management [<xref rid="B80-hematolrep-17-00023" ref-type="bibr">80</xref>].</p><p>A strategy to reduce the false positive rate in EoT PET could be the combination of visual analysis provided by DS with semiquantitative parameters, including SUVmax, SUVmean, MTV, and TLG [<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>,<xref rid="B72-hematolrep-17-00023" ref-type="bibr">72</xref>,<xref rid="B83-hematolrep-17-00023" ref-type="bibr">83</xref>,<xref rid="B86-hematolrep-17-00023" ref-type="bibr">86</xref>,<xref rid="B87-hematolrep-17-00023" ref-type="bibr">87</xref>]. Particularly, the combination of DS 5 with SUVmax &#x0003e; 5 was strongly associated with a worse PFS [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>,<xref rid="B83-hematolrep-17-00023" ref-type="bibr">83</xref>]. Vassilakopoulos et al. speculated that most DS 4 patients could register false positive findings, especially if the uptake is relatively low (SUVmax &#x0003c; 5), suggesting an RT-sparing approach in this case. The initiation of further salvage chemotherapy in patients with persistent [18F]FDG-uptake (even if SUVmax &#x02265; 10), but DS &#x0003c; 5, was discouraged because these patients frequently showed a long-term remission without further treatment [<xref rid="B86-hematolrep-17-00023" ref-type="bibr">86</xref>,<xref rid="B87-hematolrep-17-00023" ref-type="bibr">87</xref>,<xref rid="B88-hematolrep-17-00023" ref-type="bibr">88</xref>], supporting Filippi et al.&#x02019;s results, which showed an excellent outcome without relapse in all DS 4 patients [<xref rid="B83-hematolrep-17-00023" ref-type="bibr">83</xref>].</p><p>IELSG37 was a clinical trial with the objective of assessing whether RT could be omitted in PMBCL patients with CMR (DS 1&#x02013;3) after treatment with chemo-immunotherapy. This was a randomized, non-inferiority protocol, and its results have been recently reported. The total cohort was composed of 545 subjects with PMBCL; 268 of them reached CMR after therapy and were then randomly assigned to observation or RT (130 and 136 patients, respectively). PFS at 30 months was 96.2% and 95.8% in the observation and RT arm, respectively (stratified HR 1.47; 95%CI 0.34&#x02013;6.28), while OS was similar in both the groups (99% each). The findings of this study suggested, therefore, that patients with CMR after chemo-immunotherapy could safely omit consolidation RT [<xref rid="B89-hematolrep-17-00023" ref-type="bibr">89</xref>].</p><p>The optimal treatment strategy for PMBCL patients is still controversial, and more aggressive therapeutic strategies have been developed, reasonably omitting mediastinal RT [<xref rid="B90-hematolrep-17-00023" ref-type="bibr">90</xref>]. In a National Cancer Institute (NCI) phase 2 prospective study, a dose-intense DA-EPOCH regimen, especially when used with rituximab (DA-R-EPOCH), demonstrated excellent outcomes (5-year OS 97%) and tumor control, with consolidation RT administration only in 4% of patients [<xref rid="B73-hematolrep-17-00023" ref-type="bibr">73</xref>,<xref rid="B78-hematolrep-17-00023" ref-type="bibr">78</xref>,<xref rid="B91-hematolrep-17-00023" ref-type="bibr">91</xref>]. The choice of DA-EPOCH regimen as a front-line option in PMBCL patients was supported by the higher complete metabolic response rate in comparison with R-CHOP (84% vs. 70%), despite a similar OS and PFS [<xref rid="B73-hematolrep-17-00023" ref-type="bibr">73</xref>,<xref rid="B92-hematolrep-17-00023" ref-type="bibr">92</xref>]. The prognostic value of EoT PET in the context of DA-R-EPOCH therapy was demonstrated by an inferior 5-year event-free survival (92% vs. 80%) in PET-positive patients (DS 4&#x02013;5). Analogously to other therapeutic regimens, EoT PET showed a poor PPV (17%) and a high false positivity rate due to post-therapy inflammatory reaction, as histologically demonstrated by Dunleavy et al. [<xref rid="B91-hematolrep-17-00023" ref-type="bibr">91</xref>]. Probably, [18F]FDG PET/CT alone may not be accurate enough to determine the presence of residual disease after DA-R-EPOCH therapy [<xref rid="B91-hematolrep-17-00023" ref-type="bibr">91</xref>]. However, Giulino-Roth and colleagues sustained a more pronounced impact of EoT PET in predicting outcomes after DA-R-EPOCH with a sensitivity, specificity, PPV, and NPV of 76.5%, 83.3%, 41.9%, and 95.7%, respectively [<xref rid="B93-hematolrep-17-00023" ref-type="bibr">93</xref>].</p><p>A risk-adapted strategy, including PET semiquantitative data as well, would also be desirable in the DA-R-EPOCH response assessment [<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>]. EoT PET findings, including higher SUVmax, DS 4&#x02013;5, and a CT-documented residual mass, were associated with inferior PFS and increased risk of progression [<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>]. Moreover, the combination of pre- and post-treatment PET findings may better identify high-risk patients. In Pinnix et al.&#x02019;s study, the prognostic model combining high baseline TLG (&#x0003e;3941.4) with EoT DS 5 ensures sensitivity, specificity, PPV, and NPV of 50%, 98%, 86%, and 90%, respectively [<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>]. Several authors suggested integrating Deauville criteria, with MTV and TLG being good predictors in DA-R-EPOCH response assessment, improving PPV (20%) and NPV (98%) [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>]. </p><p>The integration of the DS with SUVmax could help to adequately select patients who need consolidative mediastinal RT after DA-R-EPOCH [<xref rid="B92-hematolrep-17-00023" ref-type="bibr">92</xref>,<xref rid="B94-hematolrep-17-00023" ref-type="bibr">94</xref>]. In particular, with a careful approach, RT should be considered for higher-risk patients with DS 4&#x02013;5 and SUVmax &#x02265; 5.4 [<xref rid="B80-hematolrep-17-00023" ref-type="bibr">80</xref>]. Alternatively, Melani et al. suggested that PET-negative patients, but also PET-positive ones up to DS-4 after DA-R-EPOCH, can be managed with follow-up only, since they would not benefit from consolidation RT [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>].</p><p>Serial PET imaging could effectively help to discriminate residual disease from post-treatment inflammatory reaction, and should be considered for selecting patients who require consolidation RT. An overall SUVmax decrease across serial scans is associated with non-progressive disease, while an SUVmax increase is associated with treatment failure. Even if limited by low tumor volume following therapy, MTV and TLG appeared similar, but not superior, to SUVmax [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>].</p><p>Mediastinal RT could markedly impact on a better complete response rate in the PMBCL population treated with more aggressive regimens, as the third-generation MACOP-B and VACOP-B [<xref rid="B71-hematolrep-17-00023" ref-type="bibr">71</xref>]. EoT PET evaluation may represent a useful tool at the time of RT planning, sparing mediastinal irradiation in PET-negative patients (DS 1&#x02013;3) [<xref rid="B71-hematolrep-17-00023" ref-type="bibr">71</xref>,<xref rid="B73-hematolrep-17-00023" ref-type="bibr">73</xref>,<xref rid="B95-hematolrep-17-00023" ref-type="bibr">95</xref>]. Even after the MACOP-B/VACOP-B regimen, Zinzani et al. described false positive results, underlining the importance of serial PET scans to reveal a gradual decrease in SUV value in responder patients [<xref rid="B96-hematolrep-17-00023" ref-type="bibr">96</xref>].</p><p>Hayden et al. chose a similar PET-adapted approach to guide the consolidative RT administration in PMBCL patients treated with R-CHOP/R-ICE (rituximab, ifosfamide, carboplatin, etoposide)/DA-R-EPOCH [<xref rid="B78-hematolrep-17-00023" ref-type="bibr">78</xref>]. An observational strategy was adopted for EoT PET-negative patients (DS 1&#x02013;3) with a superior 5-year time to progression (TTP) and superior OS compared to positive ones (DS 4&#x02013;5) (5-year TTP 91% vs. 68%; 5-year OS 97% vs. 87%), recommended to receive RT. Considering DS 4 patients, it remains uncertain whether it could represent a false positive post-treatment inflammatory state [<xref rid="B97-hematolrep-17-00023" ref-type="bibr">97</xref>].</p><p>EoT PET&#x02019;s prognostic role was also documented after the introduction of new treatment protocols, known as GMALL/B- ALL/NHL (alternating immunochemotherapy with intermediate-dose methotrexate for six cycles) [<xref rid="B98-hematolrep-17-00023" ref-type="bibr">98</xref>], in a Rituximab-Lymphomes Malins B (LMB)-based chemotherapy regimen [<xref rid="B99-hematolrep-17-00023" ref-type="bibr">99</xref>], and also in transplantation patients who experienced disease progression following front-line anthracycline-based chemotherapy and who underwent salvage chemotherapy. Namely, an inferior OS was observed in EoT PET non-responder patients [<xref rid="B100-hematolrep-17-00023" ref-type="bibr">100</xref>].</p><p>An open issue in this context is, surely, the best timing for performing EoT PET with respect to the end of therapy. For instance, 4 to 6 weeks after the end of chemotherapy is a widely accepted time-point, but no focused studies investigating different time-points have been conducted.</p><table-wrap position="anchor" id="hematolrep-17-00023-t004"><object-id pub-id-type="pii">hematolrep-17-00023-t004_Table 4</object-id><label>Table 4</label><caption><p>Characteristics of included studies about EOT [18F]FDG PET/CT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N. Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PET Parameters and Findings</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martelli et al. [<xref rid="B41-hematolrep-17-00023" ref-type="bibr">41</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rituximab and anthracycline-containing chemoimmunotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. Performed using liver uptake as the cut-off for PET positivity (from DS 3 to 4), better discrimination is found between high and low risk of failure, with 5-year PFS of 99% versus 68% (<italic toggle="yes">p</italic> = 0.001) and 5-year OS of 100% versus 83% (<italic toggle="yes">p</italic> = 0.001).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Casadei et al. [<xref rid="B71-hematolrep-17-00023" ref-type="bibr">71</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">151</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MACOP-B regimen with or without<break/>Rituximab</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. Patients with a negative PET scan after MACOP-B had complete response and did not undergo RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pinnix et al. [<xref rid="B72-hematolrep-17-00023" ref-type="bibr">72</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, or R-HCVAD,<break/>or R-EPOCH with or without RT</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS and SUVmax. Patients with DS 4&#x02013;5 and SUVmax &#x0003e; 5.4 after immunochemotherapy were at high risk of progression or relapse.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinzani et al. [<xref rid="B73-hematolrep-17-00023" ref-type="bibr">73</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-MACOP-B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. A PET-guided RT approach leads to reducing the use of RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chan et al. [<xref rid="B30-hematolrep-17-00023" ref-type="bibr">30</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-EPOCH-R, R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. PET provides information to evaluate the value of chemo- and RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2008</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">De Sanctis et al. [<xref rid="B70-hematolrep-17-00023" ref-type="bibr">70</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MACOP-B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. PET may be effective in therapy response assessment</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Karakatsanis et al. [<xref rid="B74-hematolrep-17-00023" ref-type="bibr">74</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">339</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP-14, R-CHOP-21</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. RT was limited to PET-positive patients with DS 3&#x02013;5. The use of RT for <break/>DS 1&#x02013;2 patients was at the discretion of the treating physician.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Held et al. [<xref rid="B76-hematolrep-17-00023" ref-type="bibr">76</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131 PMBCL patients (UNFOLDER trial)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP-21, R-CHOP-14, RT for bulky disease &#x02265;7.5 cm or extralymphatic involvement (82 patients)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. RT should be applied to poor responders that showed partial response with residual lesion at EoT PET (DS 4&#x02013;5). </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vassilakopoulos et al. [<xref rid="B75-hematolrep-17-00023" ref-type="bibr">75</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">332</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. In case of PET-negative patients, RT should be avoided. Salvage therapy in responding patients with positive PET should be avoided in absence of progression or multifocal disease.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morgenstern et al. [<xref rid="B77-hematolrep-17-00023" ref-type="bibr">77</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-EPOCH-R<break/>R-CHOP/R-ICE</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. PET provides information to evaluate the value of chemo- and RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goldschmidt et al. [<xref rid="B78-hematolrep-17-00023" ref-type="bibr">78</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP-RICE</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. EoT DS &#x02264; 3 predicts favorable outcomes.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shemmari et al. [<xref rid="B31-hematolrep-17-00023" ref-type="bibr">31</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. Salvage chemotherapy and BEAM autologous marrow transplant was performed after R-CHOP in PET-positive subjects. Better OS and PFS was demonstrated in patients who had undergone PET scan compared to those receiving RT on the bases of CT imaging. <break/></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tai et al. [<xref rid="B32-hematolrep-17-00023" ref-type="bibr">32</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. RT planning and stage migration based on PET improved survival outcome.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yang et al. [<xref rid="B33-hematolrep-17-00023" ref-type="bibr">33</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rituximab</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. PET results impact on the choice of post-induction treatment. Patients with PET-evaluation were more likely to receive RT alone (28.6% vs. 0%).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cheah et al. [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, CHOP-Q14, DA-EPOCH-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax. PET has excellent NPV but limited PPV due to the high frequency of positive scans. A negative PET is an excellent predictor of outcome. Residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Filippi et al. [<xref rid="B80-hematolrep-17-00023" ref-type="bibr">80</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rituximab-based chemotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. Almost 50% of PMBCL patients demonstrate residual disease at EoT PET. DS 5 patients are at high risk of progression and death, and they might be candidates for intensified programs.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Filippi et al. [<xref rid="B83-hematolrep-17-00023" ref-type="bibr">83</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP and R-CHOP-like chemotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. Metabolic response after chemo-immunotherapy proved to be a strong prognostic factor for PFS after radiotherapy. The use of PET for patient risk stratification allowed us to identify a subgroup of patients at high risk of progression/relapse after radiotherapy.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ceriani et al. [<xref rid="B84-hematolrep-17-00023" ref-type="bibr">84</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, R-CHOP-like, R-VACOP-B, R-MACOP-B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS and Lugano classification. PET can identify patients at higher risk of progression after RT. The prognostic value of the Lugano classification criteria was confirmed in the response assessment after RT. Patients who achieved a complete metabolic response (DS &#x02264; 3) all remain progression-free at 5 years. Patients with DS 4 also had excellent outcomes, suggesting that they do not necessarily require additional therapy, since the residual FDG uptake may not reflect persistent lymphoma.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nagle et al. [<xref rid="B85-hematolrep-17-00023" ref-type="bibr">85</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. Negative iPET and EoT PET identified patients who achieve long-term remission. Both positive iPET and EoT PET need to be better defined.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pinnix et al. [<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-R-EPOCH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MTV, TLG, and DS. A model combining baseline TLG and EoT DS identified patients at increased risk of progression.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vassilakopoulos et al. [<xref rid="B86-hematolrep-17-00023" ref-type="bibr">86</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS, Lugano classification, and SUVmax. Based on PET/CT results, no salvage chemotherapy and ASCT in subjects who respond to R-CHOPOmission of RT in a considerable amount of PET-negative subjects.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vassilakopoulos et al. [<xref rid="B87-hematolrep-17-00023" ref-type="bibr">87</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">182</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. The decision to start further salvage chemotherapy in the absence of progression of disease in conventional imaging should not be triggered by the persistence of positive PET/CT with DS &#x0003c; 5 after consolidative RT, should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined progression disease RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhou et al. [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-HCVAD, R-EPOCH, R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax. EoT PET SUVmax has correlations with survival outcome.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vassilakopoulos et al. [<xref rid="B88-hematolrep-17-00023" ref-type="bibr">88</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MACOP-B, R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. RT can be safely omitted in selected patients based on a negative EoT PET.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Velasques et al. [<xref rid="B90-hematolrep-17-00023" ref-type="bibr">90</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-EPOCH-R, R-CHOP/R-CHOEP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lugano criteria. PET may be an alternative to prevent patients from the long-term deleterious effects associated with RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dunleavy et al. [<xref rid="B91-hematolrep-17-00023" ref-type="bibr">91</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-EPOCH, DA-EPOCH-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax. PET alone is not accurate for tumor response assessment, since it showed a poor PPV = 17%. The shrinkage of residual mediastinal mass continued for 6 months, suggesting that inflammatory cells might account for FDG uptake.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shah et al. [<xref rid="B92-hematolrep-17-00023" ref-type="bibr">92</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, DA-EPOCH-R</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PET may serve as a disease assessment tool to determine the need for EoT RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Giulino-Roth et al. [<xref rid="B93-hematolrep-17-00023" ref-type="bibr">93</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-R-EPOCH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. Negative EoT PET was associated with improved EFS (95.4% vs. 54.9%, <italic toggle="yes">p</italic> &#x0003c; 0001). Patients with a positive EoT PET scan have an inferior outcome.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melani et al. [<xref rid="B101-hematolrep-17-00023" ref-type="bibr">101</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-R-EPOCH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. Serial PET imaging distinguished EoT PET-positive patients without treatment failure, thereby reducing unnecessary RT by 80%.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jain et al. [<xref rid="B94-hematolrep-17-00023" ref-type="bibr">94</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-EPOCH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. The patients with single-site residual disease on EoT PET underwent localized RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broccoli et al. [<xref rid="B95-hematolrep-17-00023" ref-type="bibr">95</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MACOP-B, R-MACOP-B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. RT was spared in those patients with a negative PET corroborative of a complete response.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinzani et al. [<xref rid="B96-hematolrep-17-00023" ref-type="bibr">96</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-MACOP-B, R-VACOP-B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax. Seven patients who had PR and presented with an ambiguous PET pattern turned out to be associated with false positives later on.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hayden et al. [<xref rid="B97-hematolrep-17-00023" ref-type="bibr">97</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. The use of a PET-adapted approach reduces RT in<break/>the majority of patients.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Romejko-Jarosinska et al. [<xref rid="B98-hematolrep-17-00023" ref-type="bibr">98</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMALL/B-ALL/NHL protocol</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">DS. EoT PET was predictive for outcome: 5-year OS and PFS were 96% and 94% in negative subjects, and 70% and 70% in positive subjects (<italic toggle="yes">p</italic> = 0.004 for OS, <italic toggle="yes">p</italic> = 0.01 for PFS).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dourthe et al. [<xref rid="B99-hematolrep-17-00023" ref-type="bibr">99</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rituximab-Lymphomes Malins B-based chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. PET provides information to evaluate the value of chemo- and RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vardhana et al. [<xref rid="B100-hematolrep-17-00023" ref-type="bibr">100</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platinum-based chemotherapy,<break/>ICE chemotherapy,<break/>with or without Rituximab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. PET provides information to evaluate the value of chemo- and RT.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinzani et al. [<xref rid="B102-hematolrep-17-00023" ref-type="bibr">102</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab, brentuximab vedotin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax and DS. DS 1&#x02013;3 was associated with complete response.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yousefirizi et al. [<xref rid="B103-hematolrep-17-00023" ref-type="bibr">103</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metabolic heterogeneity and radiomic analysis. Delta PET/CT radiomic features showed the most predictive performance, especially in specific sub-regions closer to the center of the tumor, outperforming both baseline and EoT features only and the use of PET features alone in predicting progression/relapse.</td></tr></tbody></table><table-wrap-foot><fn><p>Acronyms: DS, Deauville score; EoT, end of treatment; RT, radiotherapy; NPV, negative predictive value; PPV, positive predictive value.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec3-hematolrep-17-00023"><title>3. PMLBCL: What Is New?</title><p>New therapeutic approaches are, now, under investigation, given that the rituximab-based strategy could be insufficient in a small subset of PMBCL patients with highly aggressive disease. Therapies based on specific cellular targets consisting of membrane proteins, signal transduction pathways, programmed death ligands, etc., have been developed.</p><p>CAR-T cell therapy, for example, is one of the most promising new treatment options. This novel approach is based on the redirection of immune system T-cells against antigens expressed by tumor cells, and in the specific case of PMBCL, T-cells bind to an antigen expressed on the B-cell surface (Anti-CD19 CAR-T).</p><p>In a study performed at the NCI, the authors evaluated autologous anti-CD19 CAR T-cell therapy in 15 patients with treatment refractory CD19-positive B-cell malignancies, including 4 patients with R/R PMBCL. Of these four patients, treated with at least three prior lines of therapy, two (50%) obtained a CR, one (25%) was found to have stable disease, and another (25%) was not evaluable. Of note, both patients with a CR had ongoing responses at 12 and 22 months, respectively [<xref rid="B104-hematolrep-17-00023" ref-type="bibr">104</xref>]. A retrospective study reported the real-world outcomes of 33 patients with R/R PMBCL who received axicabtagene ciloleucel (axi-cel) off-trial [<xref rid="B105-hematolrep-17-00023" ref-type="bibr">105</xref>]. Patients had an average of three prior lines of treatment (range, 1&#x02013;9). In the intention-to-treat population, the ORR was 76%, with a 67% CR rate. 2-PFS was 64% (95%CI 49&#x02013;84%) and 2-OS was 78% (95%CI 64&#x02013;96%). However, Grade 3 or higher cytokine release syndrome was seen in 6% of patients, and grade 3 or higher neurological toxicity in 27% of patients. The Italian prospective CART-SIE evaluated the efficacy and safety of axi-cel in 70 patients with R/R PMBCL, and 190 patients with other R/R large B-cell lymphomas, after at least two prior lines of treatment [<xref rid="B106-hematolrep-17-00023" ref-type="bibr">106</xref>]. The ORR was 78% for patients with R/R PMBCL, with 50% obtaining a CR. Further, 12-month PFS was 62% (95%CI 51- 75%), and 12-month OS was 86% (95%CI 8&#x02013;95%), both significantly better than patients with other R/R large B-cell lymphomas. Similar outcomes for axi-cel in R/R PMBCL beyond second-line treatment were observed in a GLA/DRST (German Lymphoma Alliance and the German Registry for Stem Cell) registry study [<xref rid="B107-hematolrep-17-00023" ref-type="bibr">107</xref>]. Although the majority of patients enrolled in the four landmark CD19 CAR T-cell trials (ZUMA-1/axicabtagene ciloleucel, ZUMA-7/axicabtagene ciloleucel, TRANSCEND-NHL-001/lisocabtagene maraleucel, TRANSFORM/lisocabtagene maraleucel) were diagnosed with R/R DLBCL, a small number of patients with R/R PMBCL were included [<xref rid="B108-hematolrep-17-00023" ref-type="bibr">108</xref>,<xref rid="B109-hematolrep-17-00023" ref-type="bibr">109</xref>,<xref rid="B110-hematolrep-17-00023" ref-type="bibr">110</xref>,<xref rid="B111-hematolrep-17-00023" ref-type="bibr">111</xref>]. Responses were observed in all four trials, including durable remissions; however, due to the limited number of patients with R/R PMBCL, responses were grouped together. Importantly, both the ZUMA-7 and TRANSFORM trials evaluated CD19 CAR T-cell therapy as second-line treatment for R/R large B-cell lymphomas, and the authors compared this to standard care treatment (two or three cycles of investigator-selected salvage chemo-immunotherapy followed by HDT/ASCR). Both trials revealed improved response rates, EFS, and OS in patients with R/R large B-cell lymphomas treated with CD19 CAR-T cell therapy [<xref rid="B110-hematolrep-17-00023" ref-type="bibr">110</xref>,<xref rid="B111-hematolrep-17-00023" ref-type="bibr">111</xref>]. Based on the results of ZUMA-7, axi-cel was approved by the FDA in April of 2022 for adult patients with large B-cell lymphoma, including PMBCL, which is refractory to first-line chemo-immunotherapy or relapses within 12 months of first-line chemoimmunotherapy. Likewise, in June of 2022, the FDA extended the indication for lisocabtagene maraleucel (liso-cel) to include adults with large B-cell lymphoma, including PMBCL, who have refractory disease or relapse within 12 months of first-line chemo-immunotherapy based on the results of a TRANSFORM trial. A phase II trial is currently evaluating the combination of pembrolizumab plus anti-CD19 CAR-T cell therapy (either axicabtagene ciloleucel or lisocabtegene maraleucel) in patients with PMBCL with refractory disease or after two prior lines of therapy (NCT05934448). Other trials in different phases investigate CAR-20/19 T-cells (NCT04186520), sequential treatment of CD19 CAR NK- and 7x19CAR T-cells (NCT06464861), CD30.CAR T-cells (NCT04526834), WZTL-002 CAR-T cells (NCT06486051), CD79b-19 CAR T-cells (NCT06026319), P-CD19CD20-ALLO01 allogeneic CAR T-cells (NCT0601462), and cemacabtagene ansegedleuce (allogeneic) CAR T-cells (NCT06500273) for the treatment of R/R PMBCL.</p><p>A hallmark of PMBCL and cHL is, furthermore, the deregulation of the JAK-STAT pathway positively regulating PDL1 and PDL2 expression. PDL1 and PDL2 increased expression favor PMBCL survival in the thymic microenvironment. Antibodies directed against PD1 (Pembrolizumab) or PDL1 and JAK2 inhibitors (Ruxolitinib) could interfere with neoplastic cell survival mechanisms [<xref rid="B74-hematolrep-17-00023" ref-type="bibr">74</xref>]. These checkpoint inhibitors have shown efficacy in relapsed/refractory disease (R/R PMBCL) patients, leading to FDA approval in PMBCL patients after two therapy line failures [<xref rid="B97-hematolrep-17-00023" ref-type="bibr">97</xref>,<xref rid="B112-hematolrep-17-00023" ref-type="bibr">112</xref>,<xref rid="B113-hematolrep-17-00023" ref-type="bibr">113</xref>]. However, the results so far have been disappointing. A pilot phase II trial evaluating the JAK2 inhibitor ruxolitinib for the treatment of patients with R/R PMBCL (<italic toggle="yes">n</italic> = 6) resulted in rapid progression in patients [<xref rid="B114-hematolrep-17-00023" ref-type="bibr">114</xref>].</p><p>Bispecific antibodies are a novel class of T-cell redirecting drugs and are among the most promising new immune-based strategies for B-cell lymphomas to date, including PMBCL. Few patients with PMBCL are now under investigation with these new agents with encouraging results, for example, with Glofitamab and Epcoritamab, both CD20 &#x000d7; CD3 bispecific antibodies [<xref rid="B115-hematolrep-17-00023" ref-type="bibr">115</xref>,<xref rid="B116-hematolrep-17-00023" ref-type="bibr">116</xref>,<xref rid="B117-hematolrep-17-00023" ref-type="bibr">117</xref>].</p><p>In 2012, the Food and Drug Administration (FDA) approved Brentuximab vedotin (BV) for relapsed/refractory HL and anaplastic large cell lymphoma (ALCL) treatment, an anti-CD30 antibody highly expressed in this disease. This immunotherapy is under investigation even for PMBCL CD30+, although it expresses CD30 in a lower percentage. Few data are, for now, available regarding the use of BV in PMBCL. In a single-arm phase II trial consisting of 15 patients (53% with advanced stage disease, and 74% refractory to the most recent treatment), only two of them achieved PR, yielding an ORR of 13.3%. Consequently, the study was closed prematurely due to the low ORR at the mid-term evaluation [<xref rid="B9-hematolrep-17-00023" ref-type="bibr">9</xref>]. Conversely, in a recent multicenter study, the combination of nivolumab with Brentuximab vedotin in a group of 30 rrPMBCL reached an ORR of 73% with a 37% CR rate per investigator and an ORR of 70%, with a 43% complete metabolic response rate per independent review. This favorable response rate was documented by serial PET scans to confirm complete metabolic response (DS 1&#x02013;3) [<xref rid="B102-hematolrep-17-00023" ref-type="bibr">102</xref>].</p><p>This evidence could pave the way for the introduction of new combined therapies to exploit the best treatment options for all PMBCL patients.</p><p>In this varied treatment landscape of PMBCL, even more complex, more precise imaging biomarkers to assess therapy response are required [<xref rid="B74-hematolrep-17-00023" ref-type="bibr">74</xref>].</p><p>In this scenario, the conventional International Prognostic Index (IPI) has limited utility, given the young age of patients and the confined to the mediastinum disease [<xref rid="B118-hematolrep-17-00023" ref-type="bibr">118</xref>]. As shown, similarly to other forms of lymphomas, [18F]FDG PET/CT is increasingly used to monitor treatment response and guide clinical decisions in PMBCL with DS and Lugano classification that have standardized [18F]FDG PET/CT interpretation, improving the management of patients, and providing prognostic insights, too [<xref rid="B82-hematolrep-17-00023" ref-type="bibr">82</xref>,<xref rid="B101-hematolrep-17-00023" ref-type="bibr">101</xref>,<xref rid="B119-hematolrep-17-00023" ref-type="bibr">119</xref>,<xref rid="B120-hematolrep-17-00023" ref-type="bibr">120</xref>,<xref rid="B121-hematolrep-17-00023" ref-type="bibr">121</xref>].</p><p>The availability of an increasing number of biological agents, such as ICI, also requires flexibility in the interpretation of the recommendations to account for their biologic or immunomodulatory properties. Namely, tumor flare/pseudoprogression may occur during the first 2&#x02013;3 weeks after the start of treatment and is characterized by a rapid, self-limited increase in the size and FDG uptake of the disease as an expression of transient and massive immune recruitment at the cancer site. Conversely, some patients could experience hyper-progression characterized by real tumor overgrowth and poor prognosis. In 2016, the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) were proposed, representing an adaptation of the Lugano classification for the evaluation of lymphoma after immune-based treatment. The LYRIC introduced the concept of an indeterminate response (IR)&#x02014;instead of progression&#x02014;to address such lesions until a biopsy or subsequent imaging, after 12 weeks, confirming true disease progression status [<xref rid="B122-hematolrep-17-00023" ref-type="bibr">122</xref>].</p><p>Recently, emerging studies have demonstrated the utility of PET radiomics in further improving a tailored approach to treatment choice and EoT PET predictive power [<xref rid="B97-hematolrep-17-00023" ref-type="bibr">97</xref>]. Metabolic heterogeneity could be extracted from PET images and could be an interesting radiomic potential marker, given the demonstrated chemoresistance and poor outcome of patients characterized by high intralesional heterogeneity [<xref rid="B45-hematolrep-17-00023" ref-type="bibr">45</xref>]. Delta radiomics, capturing feature changes over time, could offer potential in evaluating treatment response, predicting outcome and improving clinical decision-making, with increased robustness compared to single time-point radiomics features. Intensity and textural features were extracted from EoT PET images in a Yousefirizi et al. study, and Delta PET/CT radiomic features showed the most predictive performance, especially in specific sub-regions closer to the center of the tumor, outperforming both baseline and EoT features only, and the use of PET features alone in predicting progression/relapse [<xref rid="B103-hematolrep-17-00023" ref-type="bibr">103</xref>].</p><p>Even if IELSG-37 has demonstrated that supplemental RT on the mediastinum can be omitted in patients with a negative EoT PET/CT after chemo-immunotherapy without impacting on patient outcomes, an unmet need to early identify which patients with a positive EoT PET/CT would benefit from RT remains. It is possible that circulating tumor DNA (ctDNA) might have a role in the early identification of these patients in the future, as studies have shown a high PPV of ctDNA to predict relapse. In an interesting study, ctDNA monitoring was conducted in sixteen cases of enrolled patients, and fifteen of them showed undetectable ctDNA after a median of two (range from one to five) cycles, and one refractory case presented with durable positive ctDNA. Among four relapse cases, three had prior detectable ctDNA half a month earlier before imaging manifestations of relapse [<xref rid="B123-hematolrep-17-00023" ref-type="bibr">123</xref>]. In another study, after one cycle of chemotherapy, three of four patients who reached CR at EoT already had undetectable ctDNA. One patient with positive ctDNA after one cycle needed RT to convert to CR. All the CR evaluations by PET-TC who had available ctDNA data presented undetectable ctDNA (<italic toggle="yes">n</italic> = 9) [<xref rid="B124-hematolrep-17-00023" ref-type="bibr">124</xref>]. In a recent study, ctDNA exhibited high concordance with tissue samples and genomics characterization. Moreover, ctDNA fluctuation could reflect treatment responses and indicate relapse before imaging diagnosis [<xref rid="B125-hematolrep-17-00023" ref-type="bibr">125</xref>]. Even if PMBCL is rare in children, emerging works suggest the use of whole-body MRI as an alternative tool in staging lymphomas [<xref rid="B126-hematolrep-17-00023" ref-type="bibr">126</xref>]. A systematic review of seven studies reported that in the overall stage of disease, whole-body MRI showed excellent sensitivity (~&#x02009;95.8%) and a diagnostic odds ratio of 1.19, meaning that disease on whole-body MRI had a nearly equal likelihood of being positive as PET-CT. For extranodal staging, whole-body MRI showed both excellent sensitivity and specificity (~&#x02009;90%; 97.4%, respectively), as well as area under the SROC curve (0.913; partial AUC 0.875). However, general specificity in staging is still low [<xref rid="B126-hematolrep-17-00023" ref-type="bibr">126</xref>].</p><p>Recently, a new PET radiotracer&#x02014;[<sup>68</sup>Ga]Ga-Pentixafor, a chemokine receptor&#x02014;has been developed for its expression on the surface cell of both solid and hematologic diseases such as lymphoma. Albano et al. performed a systematic review of the current literature in this setting, showing that [<sup>68</sup>Ga]Ga-Pentixafor PET can be a useful tool for the staging and treatment response evaluation, with a better diagnostic performance than [<sup>18</sup>F]FDG PET [<xref rid="B127-hematolrep-17-00023" ref-type="bibr">127</xref>]. However, specific studies with [<sup>68</sup>Ga]Ga-Pentixafor PET and PMBCL patients have not yet been published.</p></sec><sec sec-type="conclusions" id="sec4-hematolrep-17-00023"><title>4. Conclusions</title><p>Currently, PMBCL is a particular and specific entity in the panorama of lymphomas, with its own challenges and management. Different treatment lines are currently in use, with recent novel approaches that have increased PFS and OS in these patients.</p><p>This review shows how [18F]FDG PET/CT is crucial and plays a singular role in the initial diagnostic pathway to characterize the typical mediastinal mass and properly stage the patient, and that Interim PET and EoT PET are essential in evaluating the response to treatment, and, above all, distinguishing between residual disease and fibrotic/inflammatory remnants, which can lead to a change of therapy or an RT consolidation.</p><p>Given the heterogeneity and availability or choice of treatments, this review aims to resume progress in this field and evaluate how [18F]FDG PET/CT plays a central role in leading therapies, and in giving prognostic insights, too. For example, as shown a DS 1&#x02013;3, or even DS 4 -EoT, [18F]FDG PET/CT can also lead to the avoidance of consolidation RT without any repercussions on survival outcomes. Patients with higher baseline MTV or a TLG at staging time-points have worse outcomes, suggesting an intensification therapy strategy. However, it is mandatory to underline the fact that different thresholds for these parameters have been reported in different studies.</p><p>Some limitations derived from the characteristics of the papers included in the review could clearly affect our findings. First, some of these studies are characterized by small and heterogeneous cohorts, with different types of therapeutic schemes. In addition, different semiquantitative metrics without strict standardization and external cross validation are utilized in the manuscripts included in this review. It is well known that many factors can influence semiquantitative parameters and radiomics, limiting their reproducibility. Finally, most of the papers had a retrospective design or lacked randomization. Based on these facts, no meta-analysis of the data retrieved could be performed.</p><p>Considering the peculiarities of this subtype of lymphoma, as well as its rarity, some aspects of functional imaging serving PMBCL remain to be investigated. Radiomics and artificial intelligence will, surely, help in this context soon. Even if data in the literature are still emerging, the role of these new tools could be critical in addressing several outstanding open issues. Routine integration of radiomics and AI will be fundamental to collect and analyze huge amounts of data, going beyond the human eye, to direct clinical management and predict outcomes more precisely.</p><p>Prospective randomized trials with [18F]FDG PET/CT-adapted strategies are necessary to further investigate this tool as a reliable disease biomarker in this particular clinical context. Furthermore, trials exploring new therapeutic approaches, such as CAR-T or combination therapies, with more patients involved, are necessary to verify the real impact of this new treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-hematolrep-17-00023"><title>Supplementary Materials</title><p>The revised Lugano classification and the International Harmonization Project in Lymphoma supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/hematolrep17030023/s1">https://www.mdpi.com/article/10.3390/hematolrep17030023/s1</uri>.</p><supplementary-material id="hematolrep-17-00023-s001" position="float" content-type="local-data"><media xlink:href="hematolrep-17-00023-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, all of the authors; methodology, all of the authors; writing&#x02014;original draft preparation, all of the authors; writing&#x02014;review and editing, A.G.N., F.D., G.S. and A.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data supporting the reported results can be found using public scientific databases.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-hematolrep-17-00023"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.</given-names></name>
<name><surname>Di Rocco</surname><given-names>A.</given-names></name>
<name><surname>Ansuinelli</surname><given-names>M.</given-names></name>
<name><surname>Johnson</surname><given-names>P.W.M.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2017</year><volume>113</volume><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2017.01.009</pub-id><pub-id pub-id-type="pmid">28318892</pub-id>
</element-citation></ref><ref id="B2-hematolrep-17-00023"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swerdlow</surname><given-names>S.H.</given-names></name>
<name><surname>Campo</surname><given-names>E.</given-names></name>
<name><surname>Pileri</surname><given-names>S.A.</given-names></name>
<name><surname>Lee Harris</surname><given-names>N.</given-names></name>
<name><surname>Stein</surname><given-names>H.</given-names></name>
<name><surname>Siebert</surname><given-names>R.</given-names></name>
<name><surname>Advani</surname><given-names>R.</given-names></name>
<name><surname>Ghielmini</surname><given-names>M.</given-names></name>
<name><surname>Salles</surname><given-names>G.A.</given-names></name>
<name><surname>Zelenetz</surname><given-names>A.D.</given-names></name>
<etal/>
</person-group><article-title>The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>2375</fpage><pub-id pub-id-type="doi">10.1182/blood-2016-01-643569</pub-id><pub-id pub-id-type="pmid">26980727</pub-id>
</element-citation></ref><ref id="B3-hematolrep-17-00023"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name>
<name><surname>Johnson</surname><given-names>P.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2008</year><volume>68</volume><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2008.07.020</pub-id><pub-id pub-id-type="pmid">18774728</pub-id>
</element-citation></ref><ref id="B4-hematolrep-17-00023"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>P.P.</given-names></name>
<name><surname>Wang</surname><given-names>K.F.</given-names></name>
<name><surname>Xia</surname><given-names>Y.</given-names></name>
<name><surname>Bi</surname><given-names>X.W.</given-names></name>
<name><surname>Sun</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>W.Q.</given-names></name>
</person-group><article-title>Racial Patterns of Patients with Primary Mediastinal Large B-Cell Lymphoma: SEER Analysis</article-title><source>Medicine</source><year>2016</year><volume>95</volume><fpage>e4054</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000004054</pub-id><pub-id pub-id-type="pmid">27399089</pub-id>
</element-citation></ref><ref id="B5-hematolrep-17-00023"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smedby</surname><given-names>K.E.</given-names></name>
<name><surname>Hjalgrim</surname><given-names>H.</given-names></name>
</person-group><article-title>Epidemiology and Etiology of Mantle Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes</article-title><source>Semin. Cancer Biol.</source><year>2011</year><volume>21</volume><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2011.09.010</pub-id><pub-id pub-id-type="pmid">21945518</pub-id>
</element-citation></ref><ref id="B6-hematolrep-17-00023"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Armitage</surname><given-names>J.O.</given-names></name>
<name><surname>Gascoyne</surname><given-names>R.D.</given-names></name>
<name><surname>Lunning</surname><given-names>M.A.</given-names></name>
<name><surname>Cavalli</surname><given-names>F.</given-names></name>
</person-group><article-title>Non-Hodgkin Lymphoma</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>298</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32407-2</pub-id><pub-id pub-id-type="pmid">28153383</pub-id>
</element-citation></ref><ref id="B7-hematolrep-17-00023"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dabrowska-Iwanicka</surname><given-names>A.</given-names></name>
<name><surname>Walewski</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma</article-title><source>Curr. Hematol. Malig. Rep.</source><year>2014</year><volume>9</volume><fpage>273</fpage><pub-id pub-id-type="doi">10.1007/s11899-014-0219-0</pub-id><pub-id pub-id-type="pmid">24952250</pub-id>
</element-citation></ref><ref id="B8-hematolrep-17-00023"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pileri</surname><given-names>S.A.</given-names></name>
<name><surname>Gaidano</surname><given-names>G.</given-names></name>
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Falini</surname><given-names>B.</given-names></name>
<name><surname>Gaulard</surname><given-names>P.</given-names></name>
<name><surname>Zucca</surname><given-names>E.</given-names></name>
<name><surname>Pieri</surname><given-names>F.</given-names></name>
<name><surname>Berra</surname><given-names>E.</given-names></name>
<name><surname>Sabattini</surname><given-names>E.</given-names></name>
<name><surname>Ascani</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Primary Mediastinal B-Cell Lymphoma: High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB.1, and PU.1 in the Absence of Immunoglobulins</article-title><source>Am. J. Pathol.</source><year>2003</year><volume>162</volume><fpage>243</fpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63815-1</pub-id><pub-id pub-id-type="pmid">12507907</pub-id>
</element-citation></ref><ref id="B9-hematolrep-17-00023"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mottok</surname><given-names>A.</given-names></name>
<name><surname>Wright</surname><given-names>G.</given-names></name>
<name><surname>Rosenwald</surname><given-names>A.</given-names></name>
<name><surname>Ott</surname><given-names>G.</given-names></name>
<name><surname>Ramsower</surname><given-names>C.</given-names></name>
<name><surname>Campo</surname><given-names>E.</given-names></name>
<name><surname>Braziel</surname><given-names>R.M.</given-names></name>
<name><surname>Delabie</surname><given-names>J.</given-names></name>
<name><surname>Weisenburger</surname><given-names>D.D.</given-names></name>
<name><surname>Song</surname><given-names>J.Y.</given-names></name>
<etal/>
</person-group><article-title>Molecular Classification of Primary Mediastinal Large B-Cell Lymphoma Using Routinely Available Tissue Specimens</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>2401</fpage><lpage>2405</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-05-851154</pub-id><pub-id pub-id-type="pmid">30257882</pub-id>
</element-citation></ref><ref id="B10-hematolrep-17-00023"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giulino-Roth</surname><given-names>L.</given-names></name>
</person-group><article-title>How I Treat Primary Mediastinal B-Cell Lymphoma</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-04-791566</pub-id><pub-id pub-id-type="pmid">29976557</pub-id>
</element-citation></ref><ref id="B11-hematolrep-17-00023"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lees</surname><given-names>C.</given-names></name>
<name><surname>Keane</surname><given-names>C.</given-names></name>
<name><surname>Gandhi</surname><given-names>M.K.</given-names></name>
<name><surname>Gunawardana</surname><given-names>J.</given-names></name>
</person-group><article-title>Biology and Therapy of Primary Mediastinal B-Cell Lymphoma: Current Status and Future Directions</article-title><source>Br. J. Haematol.</source><year>2019</year><volume>185</volume><fpage>25</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/bjh.15778</pub-id><pub-id pub-id-type="pmid">30740662</pub-id>
</element-citation></ref><ref id="B12-hematolrep-17-00023"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savage</surname><given-names>K.J.</given-names></name>
<name><surname>Monti</surname><given-names>S.</given-names></name>
<name><surname>Kutok</surname><given-names>J.L.</given-names></name>
<name><surname>Cattoretti</surname><given-names>G.</given-names></name>
<name><surname>Neuberg</surname><given-names>D.</given-names></name>
<name><surname>De Leval</surname><given-names>L.</given-names></name>
<name><surname>Kurtin</surname><given-names>P.</given-names></name>
<name><surname>Dal Cin</surname><given-names>P.</given-names></name>
<name><surname>Ladd</surname><given-names>C.</given-names></name>
<name><surname>Feuerhake</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>The Molecular Signature of Mediastinal Large B-Cell Lymphoma Differs from That of Other Diffuse Large B-Cell Lymphomas and Shares Features with Classical Hodgkin Lymphoma</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>3871</fpage><lpage>3879</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-06-1841</pub-id><pub-id pub-id-type="pmid">12933571</pub-id>
</element-citation></ref><ref id="B13-hematolrep-17-00023"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenwald</surname><given-names>A.</given-names></name>
<name><surname>Wright</surname><given-names>G.</given-names></name>
<name><surname>Leroy</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Gaulard</surname><given-names>P.</given-names></name>
<name><surname>Gascoyne</surname><given-names>R.D.</given-names></name>
<name><surname>Chan</surname><given-names>W.C.</given-names></name>
<name><surname>Zhao</surname><given-names>T.</given-names></name>
<name><surname>Haioun</surname><given-names>C.</given-names></name>
<name><surname>Greiner</surname><given-names>T.C.</given-names></name>
<etal/>
</person-group><article-title>Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma</article-title><source>J. Exp. Med.</source><year>2003</year><volume>198</volume><fpage>851</fpage><pub-id pub-id-type="doi">10.1084/jem.20031074</pub-id><pub-id pub-id-type="pmid">12975453</pub-id>
</element-citation></ref><ref id="B14-hematolrep-17-00023"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abou-Elella</surname><given-names>A.A.</given-names></name>
<name><surname>Weisenburger</surname><given-names>D.D.</given-names></name>
<name><surname>Vose</surname><given-names>J.M.</given-names></name>
<name><surname>Kollath</surname><given-names>J.P.</given-names></name>
<name><surname>Lynch</surname><given-names>J.C.</given-names></name>
<name><surname>Bast</surname><given-names>M.A.</given-names></name>
<name><surname>Bierman</surname><given-names>P.J.</given-names></name>
<name><surname>Greiner</surname><given-names>T.C.</given-names></name>
<name><surname>Chan</surname><given-names>W.C.</given-names></name>
<name><surname>Armitage</surname><given-names>J.O.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients from the Nebraska Lymphoma Study Group</article-title><source>J. Clin. Oncol.</source><year>1999</year><volume>17</volume><fpage>784</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1200/JCO.1999.17.3.784</pub-id><pub-id pub-id-type="pmid">10071267</pub-id>
</element-citation></ref><ref id="B15-hematolrep-17-00023"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papageorgiou</surname><given-names>S.G.</given-names></name>
<name><surname>Diamantopoulos</surname><given-names>P.</given-names></name>
<name><surname>Levidou</surname><given-names>G.</given-names></name>
<name><surname>Angelopoulou</surname><given-names>M.K.</given-names></name>
<name><surname>Economopoulou</surname><given-names>P.</given-names></name>
<name><surname>Efthimiou</surname><given-names>A.</given-names></name>
<name><surname>Constantinou</surname><given-names>N.</given-names></name>
<name><surname>Katsigiannis</surname><given-names>A.</given-names></name>
<name><surname>Korkolopoulou</surname><given-names>P.</given-names></name>
<name><surname>Pappa</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Isolated Central Nervous System Relapses in Primary Mediastinal Large B-Cell Lymphoma after CHOP-like Chemotherapy with or without Rituximab</article-title><source>Hematol. Oncol.</source><year>2013</year><volume>31</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1002/hon.2012</pub-id><pub-id pub-id-type="pmid">22610484</pub-id>
</element-citation></ref><ref id="B16-hematolrep-17-00023"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elia</surname><given-names>S.</given-names></name>
<name><surname>Cecere</surname><given-names>C.</given-names></name>
<name><surname>Giampaglia</surname><given-names>F.</given-names></name>
<name><surname>Ferrante</surname><given-names>G.</given-names></name>
</person-group><article-title>Mediastinoscopy vs. Anterior Mediastinotomy in the Diagnosis of Mediastinal Lymphoma: A Randomized Trial</article-title><source>Eur. J. Cardio-Thorac. Surg.</source><year>1992</year><volume>6</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/1010-7940(92)90173-U</pub-id><pub-id pub-id-type="pmid">1497928</pub-id>
</element-citation></ref><ref id="B17-hematolrep-17-00023"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edge</surname><given-names>S.B.</given-names></name>
<name><surname>Compton</surname><given-names>C.C.</given-names></name>
</person-group><article-title>The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM</article-title><source>Ann. Surg. Oncol.</source><year>2010</year><volume>17</volume><fpage>1471</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1245/s10434-010-0985-4</pub-id><pub-id pub-id-type="pmid">20180029</pub-id>
</element-citation></ref><ref id="B18-hematolrep-17-00023"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pfau</surname><given-names>D.</given-names></name>
<name><surname>Smith</surname><given-names>D.A.</given-names></name>
<name><surname>Beck</surname><given-names>R.</given-names></name>
<name><surname>Gilani</surname><given-names>K.A.</given-names></name>
<name><surname>Gupta</surname><given-names>A.</given-names></name>
<name><surname>Caimi</surname><given-names>P.</given-names></name>
<name><surname>Ramaiya</surname><given-names>N.H.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma: A Review for Radiologists</article-title><source>Am. J. Roentgenol.</source><year>2019</year><volume>213</volume><fpage>W194</fpage><lpage>W210</lpage><pub-id pub-id-type="doi">10.2214/AJR.19.21225</pub-id><pub-id pub-id-type="pmid">31414888</pub-id>
</element-citation></ref><ref id="B19-hematolrep-17-00023"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hutchings</surname><given-names>M.</given-names></name>
<name><surname>Barrington</surname><given-names>S.</given-names></name>
</person-group><article-title>FDG-PET for the Early Treatment Monitoring, for Final Response and Follow-up Evaluation in Lymphoma</article-title><source>Clin. Transl. Imaging</source><year>2015</year><volume>3</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1007/s40336-015-0134-y</pub-id></element-citation></ref><ref id="B20-hematolrep-17-00023"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barrington</surname><given-names>S.F.</given-names></name>
<name><surname>Kluge</surname><given-names>R.</given-names></name>
</person-group><article-title>FDG PET for Therapy Monitoring in Hodgkin and Non-Hodgkin Lymphomas</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2017</year><volume>44</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1007/s00259-017-3690-8</pub-id><pub-id pub-id-type="pmid">28411336</pub-id>
</element-citation></ref><ref id="B21-hematolrep-17-00023"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Younes</surname><given-names>A.</given-names></name>
<name><surname>Hilden</surname><given-names>P.</given-names></name>
<name><surname>Coiffier</surname><given-names>B.</given-names></name>
<name><surname>Hagenbeek</surname><given-names>A.</given-names></name>
<name><surname>Salles</surname><given-names>G.</given-names></name>
<name><surname>Wilson</surname><given-names>W.</given-names></name>
<name><surname>Seymour</surname><given-names>J.F.</given-names></name>
<name><surname>Kelly</surname><given-names>K.</given-names></name>
<name><surname>Gribben</surname><given-names>J.</given-names></name>
<name><surname>Pfreunschuh</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>International Working Group Consensus Response Evaluation Criteria in Lymphoma (RECIL 2017)</article-title><source>Ann. Oncol.</source><year>2017</year><volume>28</volume><fpage>1436</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx097</pub-id><pub-id pub-id-type="pmid">28379322</pub-id>
</element-citation></ref><ref id="B22-hematolrep-17-00023"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barrington</surname><given-names>S.F.</given-names></name>
<name><surname>Mikhaeel</surname><given-names>N.G.</given-names></name>
<name><surname>Kostakoglu</surname><given-names>L.</given-names></name>
<name><surname>Meignan</surname><given-names>M.</given-names></name>
<name><surname>Hutchings</surname><given-names>M.</given-names></name>
<name><surname>M&#x000fc;eller</surname><given-names>S.P.</given-names></name>
<name><surname>Schwartz</surname><given-names>L.H.</given-names></name>
<name><surname>Zucca</surname><given-names>E.</given-names></name>
<name><surname>Fisher</surname><given-names>R.I.</given-names></name>
<name><surname>Trotman</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>3048</fpage><pub-id pub-id-type="doi">10.1200/JCO.2013.53.5229</pub-id><pub-id pub-id-type="pmid">25113771</pub-id>
</element-citation></ref><ref id="B23-hematolrep-17-00023"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Heertum</surname><given-names>R.L.</given-names></name>
<name><surname>Scarimbolo</surname><given-names>R.</given-names></name>
<name><surname>Wolodzko</surname><given-names>J.G.</given-names></name>
<name><surname>Klencke</surname><given-names>B.</given-names></name>
<name><surname>Messmann</surname><given-names>R.</given-names></name>
<name><surname>Tunc</surname><given-names>F.</given-names></name>
<name><surname>Sokol</surname><given-names>L.</given-names></name>
<name><surname>Agarwal</surname><given-names>R.</given-names></name>
<name><surname>Strafaci</surname><given-names>J.A.</given-names></name>
<name><surname>O&#x02019;Neal</surname><given-names>M.</given-names></name>
</person-group><article-title>Lugano 2014 Criteria for Assessing FDG-PET/CT in Lymphoma: An Operational Approach for Clinical Trials</article-title><source>Drug Des. Devel Ther.</source><year>2017</year><volume>11</volume><fpage>1719</fpage><pub-id pub-id-type="doi">10.2147/DDDT.S136988</pub-id><pub-id pub-id-type="pmid">28670108</pub-id>
</element-citation></ref><ref id="B24-hematolrep-17-00023"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinnix</surname><given-names>C.C.</given-names></name>
<name><surname>Ng</surname><given-names>A.K.</given-names></name>
<name><surname>Dabaja</surname><given-names>B.S.</given-names></name>
<name><surname>Milgrom</surname><given-names>S.A.</given-names></name>
<name><surname>Gunther</surname><given-names>J.R.</given-names></name>
<name><surname>David Fuller</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>G.L.</given-names></name>
<name><surname>Yehia</surname><given-names>Z.A.</given-names></name>
<name><surname>Qiao</surname><given-names>W.</given-names></name>
<name><surname>Wogan</surname><given-names>C.F.</given-names></name>
<etal/>
</person-group><article-title>Positron Emission Tomography-Computed Tomography Predictors of Progression after DA-R-EPOCH for PMBCL</article-title><source>Blood Adv.</source><year>2018</year><volume>2</volume><fpage>1334</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018017681</pub-id><pub-id pub-id-type="pmid">29895624</pub-id>
</element-citation></ref><ref id="B25-hematolrep-17-00023"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meignan</surname><given-names>M.</given-names></name>
<name><surname>Mondor</surname><given-names>G.H.</given-names></name>
</person-group><article-title>Quantitative FDG-PET: A New Biomarker in PMBCL</article-title><source>Blood</source><year>2015</year><volume>126</volume><fpage>924</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-07-653386</pub-id><pub-id pub-id-type="pmid">26294712</pub-id>
</element-citation></ref><ref id="B26-hematolrep-17-00023"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rieger</surname><given-names>M.</given-names></name>
<name><surname>&#x000d6;sterborg</surname><given-names>A.</given-names></name>
<name><surname>Pettengell</surname><given-names>R.</given-names></name>
<name><surname>White</surname><given-names>D.</given-names></name>
<name><surname>Gill</surname><given-names>D.</given-names></name>
<name><surname>Walewski</surname><given-names>J.</given-names></name>
<name><surname>Kuhnt</surname><given-names>E.</given-names></name>
<name><surname>Loeffler</surname><given-names>M.</given-names></name>
<name><surname>Pfreundschuh</surname><given-names>M.</given-names></name>
<name><surname>Ho</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Primary Mediastinal B-Cell Lymphoma Treated with CHOP-like Chemotherapy with or without Rituximab: Results of the Mabthera International Trial Group Study</article-title><source>Ann. Oncol.</source><year>2011</year><volume>22</volume><fpage>664</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq418</pub-id><pub-id pub-id-type="pmid">20724576</pub-id>
</element-citation></ref><ref id="B27-hematolrep-17-00023"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Todeschini</surname><given-names>G.</given-names></name>
<name><surname>Secchi</surname><given-names>S.</given-names></name>
<name><surname>Morra</surname><given-names>E.</given-names></name>
<name><surname>Vitolo</surname><given-names>U.</given-names></name>
<name><surname>Orlandi</surname><given-names>E.</given-names></name>
<name><surname>Pasini</surname><given-names>F.</given-names></name>
<name><surname>Gallo</surname><given-names>E.</given-names></name>
<name><surname>Ambrosetti</surname><given-names>A.</given-names></name>
<name><surname>Tecchio</surname><given-names>C.</given-names></name>
<name><surname>Tarella</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma (PMLBCL): Long-Term Results from a Retrospective Multicentre Italian Experience in 138 Patients Treated with CHOP or MACOP-B/VACOP-B</article-title><source>Br. J. Cancer</source><year>2004</year><volume>90</volume><fpage>372</fpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601460</pub-id><pub-id pub-id-type="pmid">14735179</pub-id>
</element-citation></ref><ref id="B28-hematolrep-17-00023"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savage</surname><given-names>K.J.</given-names></name>
<name><surname>Al-Rajhi</surname><given-names>N.</given-names></name>
<name><surname>Voss</surname><given-names>N.</given-names></name>
<name><surname>Paltiel</surname><given-names>C.</given-names></name>
<name><surname>Klasa</surname><given-names>R.</given-names></name>
<name><surname>Gascoyne</surname><given-names>R.D.</given-names></name>
<name><surname>Connors</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma in a Single Institution: The British Columbia Experience</article-title><source>Ann. Oncol.</source><year>2006</year><volume>17</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdj030</pub-id><pub-id pub-id-type="pmid">16236753</pub-id>
</element-citation></ref><ref id="B29-hematolrep-17-00023"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giri</surname><given-names>S.</given-names></name>
<name><surname>Bhatt</surname><given-names>V.R.</given-names></name>
<name><surname>Pathak</surname><given-names>R.</given-names></name>
<name><surname>Bociek</surname><given-names>R.G.</given-names></name>
<name><surname>Vose</surname><given-names>J.M.</given-names></name>
<name><surname>Armitage</surname><given-names>J.O.</given-names></name>
</person-group><article-title>Role of Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma in Rituximab Era: A US Population-Based Analysis</article-title><source>Am. J. Hematol.</source><year>2015</year><volume>90</volume><fpage>1052</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1002/ajh.24172</pub-id><pub-id pub-id-type="pmid">26270899</pub-id>
</element-citation></ref><ref id="B30-hematolrep-17-00023"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>E.H.L.</given-names></name>
<name><surname>Koh</surname><given-names>L.P.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>De Mel</surname><given-names>S.</given-names></name>
<name><surname>Jeyasekharan</surname><given-names>A.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>T.</given-names></name>
<name><surname>Lim</surname><given-names>S.T.</given-names></name>
<name><surname>Tao</surname><given-names>M.</given-names></name>
<name><surname>Quek</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Real World Experience of R-CHOP with or without Consolidative Radiotherapy vs DA-EPOCH-R in the First-Line Treatment of Primary Mediastinal B-Cell Lymphoma</article-title><source>Cancer Med.</source><year>2019</year><volume>8</volume><fpage>4626</fpage><lpage>4632</lpage><pub-id pub-id-type="doi">10.1002/cam4.2347</pub-id><pub-id pub-id-type="pmid">31264808</pub-id>
</element-citation></ref><ref id="B31-hematolrep-17-00023"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Shemmari</surname><given-names>S.</given-names></name>
<name><surname>Sankaranarayanan</surname><given-names>S.P.</given-names></name>
<name><surname>Krishnan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma: Clinical Features, Prognostic Factors and Survival with RCHOP in Arab Patients in the PET Scan Era</article-title><source>Lung India</source><year>2014</year><volume>31</volume><fpage>228</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.4103/0970-2113.135760</pub-id><pub-id pub-id-type="pmid">25125808</pub-id>
</element-citation></ref><ref id="B32-hematolrep-17-00023"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tai</surname><given-names>W.M.</given-names></name>
<name><surname>Quah</surname><given-names>D.</given-names></name>
<name><surname>Peng Yap</surname><given-names>S.</given-names></name>
<name><surname>Huey Tan</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>T.</given-names></name>
<name><surname>Tay</surname><given-names>K.W.</given-names></name>
<name><surname>Koo</surname><given-names>Y.X.</given-names></name>
<name><surname>Tao</surname><given-names>M.</given-names></name>
<name><surname>Quek</surname><given-names>R.</given-names></name>
<name><surname>Lim</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Primary Mediastinal Large B-Cell Lymphoma: Optimal Therapy and Prognostic Factors in 41 Consecutive Asian Patients</article-title><source>Leuk. Lymphoma</source><year>2011</year><volume>52</volume><fpage>604</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.3109/10428194.2010.550073</pub-id><pub-id pub-id-type="pmid">21261504</pub-id>
</element-citation></ref><ref id="B33-hematolrep-17-00023"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.H.</given-names></name>
<name><surname>Hsiao</surname><given-names>L.T.</given-names></name>
<name><surname>Chiou</surname><given-names>T.J.</given-names></name>
<name><surname>Yang</surname><given-names>C.F.</given-names></name>
<name><surname>Yu</surname><given-names>Y.B.</given-names></name>
<name><surname>Liu</surname><given-names>C.Y.</given-names></name>
<name><surname>Gau</surname><given-names>J.P.</given-names></name>
<name><surname>Liu</surname><given-names>J.H.</given-names></name>
<name><surname>Chen</surname><given-names>P.M.</given-names></name>
<name><surname>Tzeng</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Rituximab Induction Therapy, Survival Benefits, and the Increasing Selection of Radiotherapy as the Postinduction Treatment in Patients with Primary Mediastinal Large B-Cell Lymphoma</article-title><source>J. Chin. Med. Assoc.</source><year>2015</year><volume>78</volume><fpage>400</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.jcma.2015.02.005</pub-id><pub-id pub-id-type="pmid">25801492</pub-id>
</element-citation></ref><ref id="B34-hematolrep-17-00023"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheah</surname><given-names>C.Y.</given-names></name>
<name><surname>Hofman</surname><given-names>M.S.</given-names></name>
<name><surname>Seymour</surname><given-names>J.F.</given-names></name>
<name><surname>Ritchie</surname><given-names>D.S.</given-names></name>
<name><surname>Dickinson</surname><given-names>M.</given-names></name>
<name><surname>Wirth</surname><given-names>A.</given-names></name>
<name><surname>Prince</surname><given-names>H.M.</given-names></name>
<name><surname>Wolf</surname><given-names>M.</given-names></name>
<name><surname>Januszcewicz</surname><given-names>E.H.</given-names></name>
<name><surname>Carney</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>The Utility and Limitations of (18)F-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Primary Mediastinal B-Cell Lymphoma: Single Institution Experience and Literature Review</article-title><source>Leuk. Lymphoma</source><year>2015</year><volume>56</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.3109/10428194.2014.910656</pub-id><pub-id pub-id-type="pmid">24724780</pub-id>
</element-citation></ref><ref id="B35-hematolrep-17-00023"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Fu</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
</person-group><article-title>Value of metabolic parameters in distinguishing primary mediastinal lymphomas from thymic epithelial tumors</article-title><source>Cancer Biol. Med.</source><year>2020</year><volume>17</volume><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2019.0428</pub-id><pub-id pub-id-type="pmid">32587782</pub-id>
</element-citation></ref><ref id="B36-hematolrep-17-00023"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Lei</surname><given-names>B.</given-names></name>
<name><surname>Ruan</surname><given-names>M.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>The combination of maximum standardized uptake value and clinical parameters for improving the accuracy in distinguishing primary mediastinal lymphomas from thymic epithelial tumors</article-title><source>Quant. Imaging Med. Surg.</source><year>2024</year><volume>14</volume><fpage>1944</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.21037/qims-23-496</pub-id><pub-id pub-id-type="pmid">38415117</pub-id>
</element-citation></ref><ref id="B37-hematolrep-17-00023"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alkhawtani</surname><given-names>R.H.M.</given-names></name>
<name><surname>Noordzij</surname><given-names>W.</given-names></name>
<name><surname>Glaudemans</surname><given-names>A.W.J.M.</given-names></name>
<name><surname>van Rijn</surname><given-names>R.S.</given-names></name>
<name><surname>van der Gali&#x000eb;n</surname><given-names>H.T.</given-names></name>
<name><surname>Balink</surname><given-names>H.</given-names></name>
<name><surname>Nijland</surname><given-names>M.</given-names></name>
<name><surname>Adams</surname><given-names>H.J.A.</given-names></name>
<name><surname>Huls</surname><given-names>G.</given-names></name>
<name><surname>van Meerten</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin&#x02019;s lymphoma and primary mediastinal B-cell lymphoma</article-title><source>Nucl. Med. Commun.</source><year>2018</year><volume>39</volume><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1097/MNM.0000000000000840</pub-id><pub-id pub-id-type="pmid">29672465</pub-id>
</element-citation></ref><ref id="B38-hematolrep-17-00023"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abenavoli</surname><given-names>E.M.</given-names></name>
<name><surname>Barbetti</surname><given-names>M.</given-names></name>
<name><surname>Linguanti</surname><given-names>F.</given-names></name>
<name><surname>Mungai</surname><given-names>F.</given-names></name>
<name><surname>Nassi</surname><given-names>L.</given-names></name>
<name><surname>Puccini</surname><given-names>B.</given-names></name>
<name><surname>Romano</surname><given-names>I.</given-names></name>
<name><surname>Sordi</surname><given-names>B.</given-names></name>
<name><surname>Santi</surname><given-names>R.</given-names></name>
<name><surname>Passeri</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques</article-title><source>Cancers</source><year>2023</year><volume>15</volume><elocation-id>1931</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15071931</pub-id><pub-id pub-id-type="pmid">37046592</pub-id>
</element-citation></ref><ref id="B39-hematolrep-17-00023"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Pan</surname><given-names>T.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Zeng</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yi</surname><given-names>L.</given-names></name>
<name><surname>Zang</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Duan</surname><given-names>Q.</given-names></name>
<name><surname>Xiao</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>654854</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.654854</pub-id><pub-id pub-id-type="pmid">33869061</pub-id>
</element-citation></ref><ref id="B40-hematolrep-17-00023"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name>
<name><surname>Botto</surname><given-names>B.</given-names></name>
<name><surname>Stelitano</surname><given-names>C.</given-names></name>
<name><surname>Gotti</surname><given-names>M.</given-names></name>
<name><surname>Cabras</surname><given-names>M.G.</given-names></name>
<name><surname>Rigacci</surname><given-names>L.</given-names></name>
<name><surname>Gargantini</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Utility of Baseline 18FDG-PET/CT Functional Parameters in Defining Prognosis of Primary Mediastinal (Thymic) Large B-Cell Lymphoma</article-title><source>Blood</source><year>2015</year><volume>126</volume><fpage>950</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-12-616474</pub-id><pub-id pub-id-type="pmid">26089397</pub-id>
</element-citation></ref><ref id="B41-hematolrep-17-00023"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Zucca</surname><given-names>E.</given-names></name>
<name><surname>Luigi Zinzani</surname><given-names>P.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.</given-names></name>
<name><surname>Vitolo</surname><given-names>U.</given-names></name>
<name><surname>Stelitano</surname><given-names>C.</given-names></name>
<name><surname>Brusamolino</surname><given-names>E.</given-names></name>
<name><surname>Giuseppina Cabras</surname><given-names>M.</given-names></name>
<name><surname>Rigacci</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>[18 F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>1769</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.51.7524</pub-id><pub-id pub-id-type="pmid">24799481</pub-id>
</element-citation></ref><ref id="B42-hematolrep-17-00023"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Xia</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Ji</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Lv</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Prognostic Significance of Clinical Characteristics and 18Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Quantitative Parameters in Patients with Primary Mediastinal B-Cell Lymphoma</article-title><source>J. Int. Med. Res.</source><year>2022</year><volume>50</volume><fpage>03000605211063027</fpage><pub-id pub-id-type="doi">10.1177/03000605211063027</pub-id><pub-id pub-id-type="pmid">35001690</pub-id>
</element-citation></ref><ref id="B43-hematolrep-17-00023"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Xu-Monette</surname><given-names>Z.Y.</given-names></name>
<name><surname>Xiao</surname><given-names>L.</given-names></name>
<name><surname>Strati</surname><given-names>P.</given-names></name>
<name><surname>Hagemeister</surname><given-names>F.B.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Manyam</surname><given-names>G.C.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-Cell Lymphoma on Long-Term Follow-Up</article-title><source>Blood Cancer J.</source><year>2020</year><volume>10</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1038/s41408-020-0312-7</pub-id><pub-id pub-id-type="pmid">32366834</pub-id>
</element-citation></ref><ref id="B44-hematolrep-17-00023"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Conconi</surname><given-names>A.</given-names></name>
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name>
<name><surname>Botto</surname><given-names>B.</given-names></name>
<name><surname>Stelitano</surname><given-names>C.</given-names></name>
<name><surname>Gotti</surname><given-names>M.</given-names></name>
<name><surname>Cabras</surname><given-names>M.G.</given-names></name>
<name><surname>Rigacci</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Prognostic Models for Primary Mediastinal (Thymic) B-Cell Lymphoma Derived from 18-FDG PET/CT Quantitative Parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 Study</article-title><source>Br. J. Haematol.</source><year>2017</year><volume>178</volume><fpage>588</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1111/bjh.14728</pub-id><pub-id pub-id-type="pmid">28485042</pub-id>
</element-citation></ref><ref id="B45-hematolrep-17-00023"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Milan</surname><given-names>L.</given-names></name>
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name>
<name><surname>Cascione</surname><given-names>L.</given-names></name>
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Di Rocco</surname><given-names>A.</given-names></name>
<name><surname>Conconi</surname><given-names>A.</given-names></name>
<name><surname>Stathis</surname><given-names>A.</given-names></name>
<name><surname>Cavalli</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Metabolic Heterogeneity on Baseline 18FDG-PET/CT Scan Is a Predictor of Outcome in Primary Mediastinal B-Cell Lymphoma</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-01-826958</pub-id><pub-id pub-id-type="pmid">29720487</pub-id>
</element-citation></ref><ref id="B46-hematolrep-17-00023"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tixier</surname><given-names>F.</given-names></name>
<name><surname>Le Rest</surname><given-names>C.C.</given-names></name>
<name><surname>Hatt</surname><given-names>M.</given-names></name>
<name><surname>Albarghach</surname><given-names>N.</given-names></name>
<name><surname>Pradier</surname><given-names>O.</given-names></name>
<name><surname>Metges</surname><given-names>J.P.</given-names></name>
<name><surname>Corcos</surname><given-names>L.</given-names></name>
<name><surname>Visvikis</surname><given-names>D.</given-names></name>
</person-group><article-title>Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer</article-title><source>J. Nucl. Med.</source><year>2011</year><volume>52</volume><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.2967/jnumed.110.082404</pub-id><pub-id pub-id-type="pmid">21321270</pub-id>
</element-citation></ref><ref id="B47-hematolrep-17-00023"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chicklore</surname><given-names>S.</given-names></name>
<name><surname>Goh</surname><given-names>V.</given-names></name>
<name><surname>Siddique</surname><given-names>M.</given-names></name>
<name><surname>Roy</surname><given-names>A.</given-names></name>
<name><surname>Marsden</surname><given-names>P.K.</given-names></name>
<name><surname>Cook</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2013</year><volume>40</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/s00259-012-2247-0</pub-id><pub-id pub-id-type="pmid">23064544</pub-id>
</element-citation></ref><ref id="B48-hematolrep-17-00023"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Naqa</surname><given-names>I.</given-names></name>
<name><surname>Grigsby</surname><given-names>P.</given-names></name>
<name><surname>Apte</surname><given-names>A.</given-names></name>
<name><surname>Kidd</surname><given-names>E.</given-names></name>
<name><surname>Donnelly</surname><given-names>E.</given-names></name>
<name><surname>Khullar</surname><given-names>D.</given-names></name>
<name><surname>Chaudhari</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>Schmitt</surname><given-names>M.</given-names></name>
<name><surname>Laforest</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Exploring feature-based approaches in PET images for predicting cancer treatment outcomes</article-title><source>Pattern Recognit.</source><year>2009</year><volume>42</volume><fpage>1162</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/j.patcog.2008.08.011</pub-id><pub-id pub-id-type="pmid">20161266</pub-id>
</element-citation></ref><ref id="B49-hematolrep-17-00023"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Velden</surname><given-names>F.H.</given-names></name>
<name><surname>Cheebsumon</surname><given-names>P.</given-names></name>
<name><surname>Yaqub</surname><given-names>M.</given-names></name>
<name><surname>Smit</surname><given-names>E.F.</given-names></name>
<name><surname>Hoekstra</surname><given-names>O.S.</given-names></name>
<name><surname>Lammertsma</surname><given-names>A.A.</given-names></name>
<name><surname>Boellaard</surname><given-names>R.</given-names></name>
</person-group><article-title>Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2011</year><volume>38</volume><fpage>1636</fpage><lpage>1647</lpage><pub-id pub-id-type="doi">10.1007/s00259-011-1845-6</pub-id><pub-id pub-id-type="pmid">21617975</pub-id>
</element-citation></ref><ref id="B50-hematolrep-17-00023"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Milan</surname><given-names>L.</given-names></name>
<name><surname>Johnson</surname><given-names>P.W.M.</given-names></name>
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Presilla</surname><given-names>S.</given-names></name>
<name><surname>Giovanella</surname><given-names>L.</given-names></name>
<name><surname>Zucca</surname><given-names>E.</given-names></name>
</person-group><article-title>Baseline PET Features to Predict Prognosis in Primary Mediastinal B Cell Lymphoma: A Comparative Analysis of Different Methods for Measuring Baseline Metabolic Tumour Volume</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2019</year><volume>46</volume><fpage>1334</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1007/s00259-019-04286-8</pub-id><pub-id pub-id-type="pmid">30806751</pub-id>
</element-citation></ref><ref id="B51-hematolrep-17-00023"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cerci</surname><given-names>J.J.</given-names></name>
<name><surname>Pracchia</surname><given-names>L.F.</given-names></name>
<name><surname>Linardi</surname><given-names>C.C.G.</given-names></name>
<name><surname>Pitella</surname><given-names>F.A.</given-names></name>
<name><surname>Delbeke</surname><given-names>D.</given-names></name>
<name><surname>Izaki</surname><given-names>M.</given-names></name>
<name><surname>Trindade</surname><given-names>E.</given-names></name>
<name><surname>Soares</surname><given-names>J.</given-names></name>
<name><surname>Buccheri</surname><given-names>V.</given-names></name>
<name><surname>Meneghetti</surname><given-names>J.C.</given-names></name>
</person-group><article-title>18F-FDG PET after 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma</article-title><source>J. Nucl. Med.</source><year>2010</year><volume>51</volume><fpage>1337</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.2967/jnumed.109.073197</pub-id><pub-id pub-id-type="pmid">20720036</pub-id>
</element-citation></ref><ref id="B52-hematolrep-17-00023"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Rigacci</surname><given-names>L.</given-names></name>
<name><surname>Stefoni</surname><given-names>V.</given-names></name>
<name><surname>Broccoli</surname><given-names>A.</given-names></name>
<name><surname>Puccini</surname><given-names>B.</given-names></name>
<name><surname>Castagnoli</surname><given-names>A.</given-names></name>
<name><surname>Vaggelli</surname><given-names>L.</given-names></name>
<name><surname>Zanoni</surname><given-names>L.</given-names></name>
<name><surname>Argnani</surname><given-names>L.</given-names></name>
<name><surname>Baccarani</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Early Interim 18F-FDG PET in Hodgkin&#x02019;s Lymphoma: Evaluation on 304 Patients</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2012</year><volume>39</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s00259-011-1916-8</pub-id><pub-id pub-id-type="pmid">21894546</pub-id>
</element-citation></ref><ref id="B53-hematolrep-17-00023"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hutchings</surname><given-names>M.</given-names></name>
<name><surname>Kostakoglu</surname><given-names>L.</given-names></name>
<name><surname>Zaucha</surname><given-names>J.M.</given-names></name>
<name><surname>Malkowski</surname><given-names>B.</given-names></name>
<name><surname>Biggi</surname><given-names>A.</given-names></name>
<name><surname>Danielewicz</surname><given-names>I.</given-names></name>
<name><surname>Loft</surname><given-names>A.</given-names></name>
<name><surname>Specht</surname><given-names>L.</given-names></name>
<name><surname>Lamonica</surname><given-names>D.</given-names></name>
<name><surname>Czuczman</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>In Vivo Treatment Sensitivity Testing with Positron Emission Tomography/Computed Tomography after One Cycle of Chemotherapy for Hodgkin Lymphoma</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>2705</fpage><lpage>2711</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.53.2838</pub-id><pub-id pub-id-type="pmid">25071108</pub-id>
</element-citation></ref><ref id="B54-hematolrep-17-00023"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nanni</surname><given-names>C.</given-names></name>
<name><surname>Kobe</surname><given-names>C.</given-names></name>
<name><surname>Bae&#x000df;ler</surname><given-names>B.</given-names></name>
<name><surname>Baues</surname><given-names>C.</given-names></name>
<name><surname>Boellaard</surname><given-names>R.</given-names></name>
<name><surname>Borchmann</surname><given-names>P.</given-names></name>
<name><surname>Buck</surname><given-names>A.</given-names></name>
<name><surname>Buvat</surname><given-names>I.</given-names></name>
<name><surname>Chapuy</surname><given-names>B.</given-names></name>
<name><surname>Cheson</surname><given-names>B.D.</given-names></name>
<etal/>
</person-group><article-title>European Association of Nuclear Medicine (EANM) Focus 4 Consensus Recommendations: Molecular Imaging and Therapy in Haematological Tumours</article-title><source>Lancet Haematol.</source><year>2023</year><volume>10</volume><fpage>e367</fpage><lpage>e381</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(23)00030-3</pub-id><pub-id pub-id-type="pmid">37142345</pub-id>
</element-citation></ref><ref id="B55-hematolrep-17-00023"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x000fc;hrsen</surname><given-names>U.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>S.</given-names></name>
<name><surname>Hertenstein</surname><given-names>B.</given-names></name>
<name><surname>Thomssen</surname><given-names>H.</given-names></name>
<name><surname>Kotzerke</surname><given-names>J.</given-names></name>
<name><surname>Mesters</surname><given-names>R.</given-names></name>
<name><surname>Berdel</surname><given-names>W.E.</given-names></name>
<name><surname>Franzius</surname><given-names>C.</given-names></name>
<name><surname>Kroschinsky</surname><given-names>F.</given-names></name>
<name><surname>Weckesser</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>2024</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.76.8093</pub-id><pub-id pub-id-type="pmid">29750632</pub-id>
</element-citation></ref><ref id="B56-hematolrep-17-00023"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Barca</surname><given-names>E.</given-names></name>
<name><surname>Canales</surname><given-names>M.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>M.</given-names></name>
<name><surname>Vidal</surname><given-names>M.J.</given-names></name>
<name><surname>Salar</surname><given-names>A.</given-names></name>
<name><surname>Oriol</surname><given-names>A.</given-names></name>
<name><surname>Bargay</surname><given-names>J.</given-names></name>
<name><surname>Bello</surname><given-names>J.L.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>J.J.</given-names></name>
<name><surname>Tom&#x000e1;s</surname><given-names>J.F.</given-names></name>
<etal/>
</person-group><article-title>Predictive Value of Interim 18F-FDG-PET/CT for Event-Free Survival in Patients with Diffuse Large B-Cell Lymphoma Homogenously Treated in a Phase II Trial with Six Cycles of R-CHOP-14 plus Pegfilgrastim as First-Line Treatment</article-title><source>Nucl. Med. Commun.</source><year>2013</year><volume>34</volume><fpage>946</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1097/MNM.0b013e328363c695</pub-id><pub-id pub-id-type="pmid">23880897</pub-id>
</element-citation></ref><ref id="B57-hematolrep-17-00023"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mamot</surname><given-names>C.</given-names></name>
<name><surname>Klingbiel</surname><given-names>D.</given-names></name>
<name><surname>Hitz</surname><given-names>F.</given-names></name>
<name><surname>Renner</surname><given-names>C.</given-names></name>
<name><surname>Pabst</surname><given-names>T.</given-names></name>
<name><surname>Driessen</surname><given-names>C.</given-names></name>
<name><surname>Mey</surname><given-names>U.</given-names></name>
<name><surname>Pless</surname><given-names>M.</given-names></name>
<name><surname>Bargetzi</surname><given-names>M.</given-names></name>
<name><surname>Krasniqi</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP-14 (SAKK 38/07)</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>2523</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.9846</pub-id><pub-id pub-id-type="pmid">26150440</pub-id>
</element-citation></ref><ref id="B58-hematolrep-17-00023"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itti</surname><given-names>E.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Dupuis</surname><given-names>J.</given-names></name>
<name><surname>Paone</surname><given-names>G.</given-names></name>
<name><surname>Capacchione</surname><given-names>D.</given-names></name>
<name><surname>Rahmouni</surname><given-names>A.</given-names></name>
<name><surname>Haioun</surname><given-names>C.</given-names></name>
<name><surname>Meignan</surname><given-names>M.</given-names></name>
</person-group><article-title>Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy</article-title><source>J. Nucl. Med.</source><year>2009</year><volume>50</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.2967/jnumed.108.057703</pub-id><pub-id pub-id-type="pmid">19289424</pub-id>
</element-citation></ref><ref id="B59-hematolrep-17-00023"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zanoni</surname><given-names>L.</given-names></name>
<name><surname>Mattana</surname><given-names>F.</given-names></name>
<name><surname>Calabr&#x000f2;</surname><given-names>D.</given-names></name>
<name><surname>Paccagnella</surname><given-names>A.</given-names></name>
<name><surname>Broccoli</surname><given-names>A.</given-names></name>
<name><surname>Nanni</surname><given-names>C.</given-names></name>
<name><surname>Fanti</surname><given-names>S.</given-names></name>
</person-group><article-title>Overview and Recent Advances in PET/CT Imaging in Lymphoma and Multiple Myeloma</article-title><source>Eur. J. Radiol.</source><year>2021</year><volume>141</volume><fpage>109793</fpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2021.109793</pub-id><pub-id pub-id-type="pmid">34148014</pub-id>
</element-citation></ref><ref id="B60-hematolrep-17-00023"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>H.J.A.</given-names></name>
<name><surname>Kwee</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Controversies on the Prognostic Value of Interim FDG-PET in Advanced-Stage Hodgkin Lymphoma</article-title><source>Eur. J. Haematol.</source><year>2016</year><volume>97</volume><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1111/ejh.12791</pub-id><pub-id pub-id-type="pmid">27528557</pub-id>
</element-citation></ref><ref id="B61-hematolrep-17-00023"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>H.J.A.</given-names></name>
<name><surname>Kwee</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Proportion of False-Positive Lesions at Interim and End-of-Treatment FDG-PET in Lymphoma as Determined by Histology: Systematic Review and Meta-Analysis</article-title><source>Eur. J. Radiol.</source><year>2016</year><volume>85</volume><fpage>1963</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2016.08.011</pub-id><pub-id pub-id-type="pmid">27776647</pub-id>
</element-citation></ref><ref id="B62-hematolrep-17-00023"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lazarovici</surname><given-names>J.</given-names></name>
<name><surname>Terroir</surname><given-names>M.</given-names></name>
<name><surname>Arfi-Rouche</surname><given-names>J.</given-names></name>
<name><surname>Michot</surname><given-names>J.M.</given-names></name>
<name><surname>Mussot</surname><given-names>S.</given-names></name>
<name><surname>Florea</surname><given-names>V.</given-names></name>
<name><surname>Ghigna</surname><given-names>M.R.</given-names></name>
<name><surname>Dartigues</surname><given-names>P.</given-names></name>
<name><surname>Petrovanu</surname><given-names>C.</given-names></name>
<name><surname>Danu</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Poor Predictive Value of Positive Interim FDG-PET/CT in Primary Mediastinal Large B-Cell Lymphoma</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2017</year><volume>44</volume><fpage>2018</fpage><lpage>2024</lpage><pub-id pub-id-type="doi">10.1007/s00259-017-3758-5</pub-id><pub-id pub-id-type="pmid">28634685</pub-id>
</element-citation></ref><ref id="B63-hematolrep-17-00023"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avigdor</surname><given-names>A.</given-names></name>
<name><surname>Sirotkin</surname><given-names>T.</given-names></name>
<name><surname>Kedmi</surname><given-names>M.</given-names></name>
<name><surname>Ribakovsy</surname><given-names>E.</given-names></name>
<name><surname>Berkowicz</surname><given-names>M.</given-names></name>
<name><surname>Davidovitz</surname><given-names>Y.</given-names></name>
<name><surname>Kneller</surname><given-names>A.</given-names></name>
<name><surname>Merkel</surname><given-names>D.</given-names></name>
<name><surname>Volchek</surname><given-names>Y.</given-names></name>
<name><surname>Davidson</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>The Impact of R-VACOP-B and Interim FDG-PET/CT on Outcome in Primary Mediastinal Large B Cell Lymphoma</article-title><source>Ann. Hematol.</source><year>2014</year><volume>93</volume><fpage>1297</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1007/s00277-014-2043-y</pub-id><pub-id pub-id-type="pmid">24595734</pub-id>
</element-citation></ref><ref id="B64-hematolrep-17-00023"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>W.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>You</surname><given-names>J.</given-names></name>
<name><surname>Guo</surname><given-names>R.</given-names></name>
<name><surname>Shi</surname><given-names>Q.</given-names></name>
<name><surname>Dong</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>R.</given-names></name>
<name><surname>Cheng</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>P.</given-names></name>
<name><surname>Qian</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Deauville Score Evaluation of Interim PET/CT in Primary Mediastinal Large B-Cell Lymphoma</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2021</year><volume>48</volume><fpage>3347</fpage><lpage>3350</lpage><pub-id pub-id-type="doi">10.1007/s00259-021-05310-6</pub-id><pub-id pub-id-type="pmid">33758951</pub-id>
</element-citation></ref><ref id="B65-hematolrep-17-00023"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>H.J.A.</given-names></name>
<name><surname>Kwee</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Proportion of False-Positive Follow-up FDG-PET Scans in Lymphoma: Systematic Review and Meta-Analysis</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2019</year><volume>141</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.05.010</pub-id><pub-id pub-id-type="pmid">31252322</pub-id>
</element-citation></ref><ref id="B66-hematolrep-17-00023"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avril</surname><given-names>N.</given-names></name>
</person-group><article-title>GLUT1 Expression in Tissue and 18F-FDG Uptake</article-title><source>J. Nucl. Med.</source><year>2004</year><volume>45</volume><fpage>930</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">15181126</pub-id>
</element-citation></ref><ref id="B67-hematolrep-17-00023"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>H.S.</given-names></name>
<name><surname>Escal&#x000f3;n</surname><given-names>M.P.</given-names></name>
<name><surname>Hsiao</surname><given-names>B.</given-names></name>
<name><surname>Serafini</surname><given-names>A.</given-names></name>
<name><surname>Lossos</surname><given-names>I.S.</given-names></name>
</person-group><article-title>High Incidence of False-Positive PET Scans in Patients with Aggressive Non-Hodgkin&#x02019;s Lymphoma Treated with Rituximab-Containing Regimens</article-title><source>Ann. Oncol.</source><year>2009</year><volume>20</volume><fpage>309</fpage><pub-id pub-id-type="doi">10.1093/annonc/mdn629</pub-id><pub-id pub-id-type="pmid">18842613</pub-id>
</element-citation></ref><ref id="B68-hematolrep-17-00023"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burggraaff</surname><given-names>C.N.</given-names></name>
<name><surname>de Jong</surname><given-names>A.</given-names></name>
<name><surname>Hoekstra</surname><given-names>O.S.</given-names></name>
<name><surname>Hoetjes</surname><given-names>N.J.</given-names></name>
<name><surname>Nievelstein</surname><given-names>R.A.J.</given-names></name>
<name><surname>Jansma</surname><given-names>E.P.</given-names></name>
<name><surname>Heymans</surname><given-names>M.W.</given-names></name>
<name><surname>de Vet</surname><given-names>H.C.W.</given-names></name>
<name><surname>Zijlstra</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Predictive Value of Interim Positron Emission Tomography in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><year>2019</year><volume>46</volume><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s00259-018-4103-3</pub-id><pub-id pub-id-type="pmid">30141066</pub-id>
</element-citation></ref><ref id="B69-hematolrep-17-00023"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Tani</surname><given-names>M.</given-names></name>
<name><surname>Trisolini</surname><given-names>R.</given-names></name>
<name><surname>Fanti</surname><given-names>S.</given-names></name>
<name><surname>Stefoni</surname><given-names>V.</given-names></name>
<name><surname>Alifano</surname><given-names>M.</given-names></name>
<name><surname>Castellucci</surname><given-names>P.</given-names></name>
<name><surname>Musuraca</surname><given-names>G.</given-names></name>
<name><surname>Dalpiaz</surname><given-names>G.</given-names></name>
<name><surname>Alinari</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Histological Verification of Positive Positron Emission Tomography Findings in the Follow-up of Patients with Mediastinal Lymphoma</article-title><source>Haematologica</source><year>2007</year><volume>92</volume><fpage>771</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.3324/haematol.10798</pub-id><pub-id pub-id-type="pmid">17550849</pub-id>
</element-citation></ref><ref id="B70-hematolrep-17-00023"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Sanctis</surname><given-names>V.</given-names></name>
<name><surname>Finolezzi</surname><given-names>E.</given-names></name>
<name><surname>Osti</surname><given-names>M.F.</given-names></name>
<name><surname>Grapulin</surname><given-names>L.</given-names></name>
<name><surname>Alf&#x000f2;</surname><given-names>M.</given-names></name>
<name><surname>Pescarmona</surname><given-names>E.</given-names></name>
<name><surname>Berardi</surname><given-names>F.</given-names></name>
<name><surname>Natalino</surname><given-names>F.</given-names></name>
<name><surname>Moleti</surname><given-names>M.L.</given-names></name>
<name><surname>Di Rocco</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2008</year><volume>72</volume><fpage>1154</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2008.02.036</pub-id><pub-id pub-id-type="pmid">18472357</pub-id>
</element-citation></ref><ref id="B71-hematolrep-17-00023"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casadei</surname><given-names>B.</given-names></name>
<name><surname>Argnani</surname><given-names>L.</given-names></name>
<name><surname>Morigi</surname><given-names>A.</given-names></name>
<name><surname>Lolli</surname><given-names>G.</given-names></name>
<name><surname>Broccoli</surname><given-names>A.</given-names></name>
<name><surname>Pellegrini</surname><given-names>C.</given-names></name>
<name><surname>Nanni</surname><given-names>L.</given-names></name>
<name><surname>Stefoni</surname><given-names>V.</given-names></name>
<name><surname>Coppola</surname><given-names>P.E.</given-names></name>
<name><surname>Carella</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Treatment and Outcomes of Primary Mediastinal B Cell Lymphoma: A Three-Decade Monocentric Experience with 151 Patients</article-title><source>Ann. Hematol.</source><year>2021</year><volume>100</volume><fpage>2261</fpage><pub-id pub-id-type="doi">10.1007/s00277-020-04364-0</pub-id><pub-id pub-id-type="pmid">33305333</pub-id>
</element-citation></ref><ref id="B72-hematolrep-17-00023"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinnix</surname><given-names>C.C.</given-names></name>
<name><surname>Dabaja</surname><given-names>B.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.A.</given-names></name>
<name><surname>Chuang</surname><given-names>H.H.</given-names></name>
<name><surname>Costelloe</surname><given-names>C.</given-names></name>
<name><surname>Wogan</surname><given-names>C.F.</given-names></name>
<name><surname>Reed</surname><given-names>V.</given-names></name>
<name><surname>Romaguera</surname><given-names>J.E.</given-names></name>
<name><surname>Neelapu</surname><given-names>S.</given-names></name>
<name><surname>Oki</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Single Institutional Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2015</year><volume>92</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.02.006</pub-id><pub-id pub-id-type="pmid">25863759</pub-id>
</element-citation></ref><ref id="B73-hematolrep-17-00023"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Broccoli</surname><given-names>A.</given-names></name>
<name><surname>Casadei</surname><given-names>B.</given-names></name>
<name><surname>Stefoni</surname><given-names>V.</given-names></name>
<name><surname>Pellegrini</surname><given-names>C.</given-names></name>
<name><surname>Gandolfi</surname><given-names>L.</given-names></name>
<name><surname>Maglie</surname><given-names>R.</given-names></name>
<name><surname>Argnani</surname><given-names>L.</given-names></name>
<name><surname>Pileri</surname><given-names>S.</given-names></name>
<name><surname>Fanti</surname><given-names>S.</given-names></name>
</person-group><article-title>The Role of Rituximab and Positron Emission Tomography in the Treatment of Primary Mediastinal Large B-Cell Lymphoma: Experience on 74 Patients</article-title><source>Hematol. Oncol.</source><year>2015</year><volume>33</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1002/hon.2172</pub-id><pub-id pub-id-type="pmid">25256959</pub-id>
</element-citation></ref><ref id="B74-hematolrep-17-00023"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karakatsanis</surname><given-names>S.J.</given-names></name>
<name><surname>Bouzani</surname><given-names>M.</given-names></name>
<name><surname>Symeonidis</surname><given-names>A.</given-names></name>
<name><surname>Angelopoulou</surname><given-names>M.K.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>S.G.</given-names></name>
<name><surname>Michail</surname><given-names>M.</given-names></name>
<name><surname>Gainaru</surname><given-names>G.</given-names></name>
<name><surname>Kourti</surname><given-names>G.</given-names></name>
<name><surname>Sachanas</surname><given-names>S.</given-names></name>
<name><surname>Kalpadakis</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Real-Life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-Cell Lymphoma</article-title><source>In Vivo</source><year>2022</year><volume>36</volume><fpage>1302</fpage><pub-id pub-id-type="doi">10.21873/invivo.12831</pub-id><pub-id pub-id-type="pmid">35478115</pub-id>
</element-citation></ref><ref id="B75-hematolrep-17-00023"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassilakopoulos</surname><given-names>T.P.</given-names></name>
<name><surname>Michail</surname><given-names>M.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>S.</given-names></name>
<name><surname>Kourti</surname><given-names>G.</given-names></name>
<name><surname>Angelopoulou</surname><given-names>M.K.</given-names></name>
<name><surname>Panitsas</surname><given-names>F.</given-names></name>
<name><surname>Sachanas</surname><given-names>S.</given-names></name>
<name><surname>Kalpadakis</surname><given-names>C.</given-names></name>
<name><surname>Katodritou</surname><given-names>E.</given-names></name>
<name><surname>Leonidopoulou</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1002/onco.13789</pub-id><pub-id pub-id-type="pmid">33870594</pub-id>
</element-citation></ref><ref id="B76-hematolrep-17-00023"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Held</surname><given-names>G.</given-names></name>
<name><surname>Thurner</surname><given-names>L.</given-names></name>
<name><surname>Poeschel</surname><given-names>V.</given-names></name>
<name><surname>Ott</surname><given-names>G.</given-names></name>
<name><surname>Schmidt</surname><given-names>C.</given-names></name>
<name><surname>Christofyllakis</surname><given-names>K.</given-names></name>
<name><surname>Viardot</surname><given-names>A.</given-names></name>
<name><surname>Borchmann</surname><given-names>P.</given-names></name>
<name><surname>Engel-Riedel</surname><given-names>W.</given-names></name>
<name><surname>Frickhofen</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial</article-title><source>Hemasphere</source><year>2023</year><volume>7</volume><fpage>e917</fpage><pub-id pub-id-type="doi">10.1097/HS9.0000000000000917</pub-id><pub-id pub-id-type="pmid">37427145</pub-id>
</element-citation></ref><ref id="B77-hematolrep-17-00023"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgenstern</surname><given-names>Y.</given-names></name>
<name><surname>Aumann</surname><given-names>S.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>N.</given-names></name>
<name><surname>Gatt</surname><given-names>M.E.</given-names></name>
<name><surname>Nachmias</surname><given-names>B.</given-names></name>
<name><surname>Horowitz</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Dose-Adjusted EPOCH-R Is Not Superior to Sequential R-CHOP/R-ICE as a Frontline Treatment for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Bi-Center Retrospective Study</article-title><source>Cancer Med.</source><year>2021</year><volume>10</volume><fpage>8866</fpage><lpage>8875</lpage><pub-id pub-id-type="doi">10.1002/cam4.4387</pub-id><pub-id pub-id-type="pmid">34816617</pub-id>
</element-citation></ref><ref id="B78-hematolrep-17-00023"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldschmidt</surname><given-names>N.</given-names></name>
<name><surname>Kleinstern</surname><given-names>G.</given-names></name>
<name><surname>Orevi</surname><given-names>M.</given-names></name>
<name><surname>Paltiel</surname><given-names>O.</given-names></name>
<name><surname>Ben-Yehuda</surname><given-names>D.</given-names></name>
<name><surname>Gural</surname><given-names>A.</given-names></name>
<name><surname>Libster</surname><given-names>D.</given-names></name>
<name><surname>Lavie</surname><given-names>D.</given-names></name>
<name><surname>Gatt</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma Patients Treated with Sequential RCHOP-RICE Regimen without Radiotherapy</article-title><source>Cancer Chemother. Pharmacol.</source><year>2016</year><volume>77</volume><fpage>1053</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3024-8</pub-id><pub-id pub-id-type="pmid">27056383</pub-id>
</element-citation></ref><ref id="B79-hematolrep-17-00023"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Juweid</surname><given-names>M.E.</given-names></name>
<name><surname>Stroobants</surname><given-names>S.</given-names></name>
<name><surname>Hoekstra</surname><given-names>O.S.</given-names></name>
<name><surname>Mottaghy</surname><given-names>F.M.</given-names></name>
<name><surname>Dietlein</surname><given-names>M.</given-names></name>
<name><surname>Guermazi</surname><given-names>A.</given-names></name>
<name><surname>Wiseman</surname><given-names>G.A.</given-names></name>
<name><surname>Kostakoglu</surname><given-names>L.</given-names></name>
<name><surname>Scheidhauer</surname><given-names>K.</given-names></name>
<name><surname>Buck</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.2305</pub-id><pub-id pub-id-type="pmid">17242397</pub-id>
</element-citation></ref><ref id="B80-hematolrep-17-00023"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filippi</surname><given-names>A.R.</given-names></name>
<name><surname>Piva</surname><given-names>C.</given-names></name>
<name><surname>Giunta</surname><given-names>F.</given-names></name>
<name><surname>Bell&#x000f2;</surname><given-names>M.</given-names></name>
<name><surname>Chiappella</surname><given-names>A.</given-names></name>
<name><surname>Caracciolo</surname><given-names>D.</given-names></name>
<name><surname>Zotta</surname><given-names>M.</given-names></name>
<name><surname>Douroukas</surname><given-names>A.</given-names></name>
<name><surname>Ragona</surname><given-names>R.</given-names></name>
<name><surname>Vitolo</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Radiation Therapy in Primary Mediastinal B-Cell Lymphoma with Positron Emission Tomography Positivity after Rituximab Chemotherapy</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2013</year><volume>87</volume><fpage>311</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.05.053</pub-id><pub-id pub-id-type="pmid">23916170</pub-id>
</element-citation></ref><ref id="B81-hematolrep-17-00023"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meignan</surname><given-names>M.</given-names></name>
<name><surname>Barrington</surname><given-names>S.</given-names></name>
<name><surname>Itti</surname><given-names>E.</given-names></name>
<name><surname>Gallamini</surname><given-names>A.</given-names></name>
<name><surname>Haioun</surname><given-names>C.</given-names></name>
<name><surname>Polliack</surname><given-names>A.</given-names></name>
</person-group><article-title>Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma Held in Menton, France, 3&#x02013;5 October 2012</article-title><source>Leuk. Lymphoma</source><year>2014</year><volume>55</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.3109/10428194.2013.802784</pub-id><pub-id pub-id-type="pmid">23763460</pub-id>
</element-citation></ref><ref id="B82-hematolrep-17-00023"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheson</surname><given-names>B.D.</given-names></name>
<name><surname>Fisher</surname><given-names>R.I.</given-names></name>
<name><surname>Barrington</surname><given-names>S.F.</given-names></name>
<name><surname>Cavalli</surname><given-names>F.</given-names></name>
<name><surname>Schwartz</surname><given-names>L.H.</given-names></name>
<name><surname>Zucca</surname><given-names>E.</given-names></name>
<name><surname>Lister</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>3059</fpage><lpage>3067</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.54.8800</pub-id><pub-id pub-id-type="pmid">25113753</pub-id>
</element-citation></ref><ref id="B83-hematolrep-17-00023"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filippi</surname><given-names>A.R.</given-names></name>
<name><surname>Piva</surname><given-names>C.</given-names></name>
<name><surname>Levis</surname><given-names>M.</given-names></name>
<name><surname>Chiappella</surname><given-names>A.</given-names></name>
<name><surname>Caracciolo</surname><given-names>D.</given-names></name>
<name><surname>Bell&#x000f2;</surname><given-names>M.</given-names></name>
<name><surname>Bisi</surname><given-names>G.</given-names></name>
<name><surname>Vitolo</surname><given-names>U.</given-names></name>
<name><surname>Ricardi</surname><given-names>U.</given-names></name>
</person-group><article-title>Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2016</year><volume>95</volume><fpage>1239</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2016.02.057</pub-id><pub-id pub-id-type="pmid">27130796</pub-id>
</element-citation></ref><ref id="B84-hematolrep-17-00023"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Gospodarowicz</surname><given-names>M.K.</given-names></name>
<name><surname>Ricardi</surname><given-names>U.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name>
<name><surname>Chiappella</surname><given-names>A.</given-names></name>
<name><surname>Stelitano</surname><given-names>C.</given-names></name>
<name><surname>Balzarotti</surname><given-names>M.</given-names></name>
<name><surname>Cabrera</surname><given-names>M.E.</given-names></name>
<name><surname>Cunningham</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2017</year><volume>97</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2016.09.031</pub-id><pub-id pub-id-type="pmid">27839910</pub-id>
</element-citation></ref><ref id="B85-hematolrep-17-00023"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagle</surname><given-names>S.J.</given-names></name>
<name><surname>Chong</surname><given-names>E.A.</given-names></name>
<name><surname>Chekol</surname><given-names>S.</given-names></name>
<name><surname>Shah</surname><given-names>N.N.</given-names></name>
<name><surname>Nasta</surname><given-names>S.D.</given-names></name>
<name><surname>Glatstein</surname><given-names>E.</given-names></name>
<name><surname>Plastaras</surname><given-names>J.P.</given-names></name>
<name><surname>Torigian</surname><given-names>D.A.</given-names></name>
<name><surname>Schuster</surname><given-names>S.J.</given-names></name>
<name><surname>Svoboda</surname><given-names>J.</given-names></name>
</person-group><article-title>The Role of FDG-PET Imaging as a Prognostic Marker of Outcome in Primary Mediastinal B-Cell Lymphoma</article-title><source>Cancer Med.</source><year>2015</year><volume>4</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1002/cam4.322</pub-id><pub-id pub-id-type="pmid">25205600</pub-id>
</element-citation></ref><ref id="B86-hematolrep-17-00023"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassilakopoulos</surname><given-names>T.P.</given-names></name>
<name><surname>Pangalis</surname><given-names>G.A.</given-names></name>
<name><surname>Chatziioannou</surname><given-names>S.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>S.</given-names></name>
<name><surname>Angelopoulou</surname><given-names>M.K.</given-names></name>
<name><surname>Galani</surname><given-names>Z.</given-names></name>
<name><surname>Kourti</surname><given-names>G.</given-names></name>
<name><surname>Prassopoulos</surname><given-names>V.</given-names></name>
<name><surname>Leonidopoulou</surname><given-names>T.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>PET/CT in Primary Mediastinal Large B-Cell Lymphoma Responding to Rituximab-CHOP: An Analysis of 106 Patients Regarding Prognostic Significance and Implications for Subsequent Radiotherapy</article-title><source>Leukemia</source><year>2016</year><volume>30</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/leu.2015.120</pub-id><pub-id pub-id-type="pmid">25971363</pub-id>
</element-citation></ref><ref id="B87-hematolrep-17-00023"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassilakopoulos</surname><given-names>T.P.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>S.G.</given-names></name>
<name><surname>Angelopoulou</surname><given-names>M.K.</given-names></name>
<name><surname>Chatziioannou</surname><given-names>S.</given-names></name>
<name><surname>Prassopoulos</surname><given-names>V.</given-names></name>
<name><surname>Karakatsanis</surname><given-names>S.</given-names></name>
<name><surname>Arapaki</surname><given-names>M.</given-names></name>
<name><surname>Mellios</surname><given-names>Z.</given-names></name>
<name><surname>Sachanas</surname><given-names>S.</given-names></name>
<name><surname>Kalpadakis</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Positron Emission Tomography after Response to Rituximab-CHOP in Primary Mediastinal Large B-Cell Lymphoma: Impact on Outcomes and Radiotherapy Strategies</article-title><source>Ann. Hematol.</source><year>2021</year><volume>100</volume><fpage>2279</fpage><lpage>2292</lpage><pub-id pub-id-type="doi">10.1007/s00277-021-04421-2</pub-id><pub-id pub-id-type="pmid">33523289</pub-id>
</element-citation></ref><ref id="B88-hematolrep-17-00023"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassilakopoulos</surname><given-names>T.P.</given-names></name>
<name><surname>Pangalis</surname><given-names>G.A.</given-names></name>
<name><surname>Katsigiannis</surname><given-names>A.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>S.G.</given-names></name>
<name><surname>Constantinou</surname><given-names>N.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<name><surname>Zorbala</surname><given-names>A.</given-names></name>
<name><surname>Vrakidou</surname><given-names>E.</given-names></name>
<name><surname>Repoussis</surname><given-names>P.</given-names></name>
<name><surname>Poziopoulos</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2011-0275</pub-id><pub-id pub-id-type="pmid">22282906</pub-id>
</element-citation></ref><ref id="B89-hematolrep-17-00023"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martelli</surname><given-names>M.</given-names></name>
<name><surname>Ceriani</surname><given-names>L.</given-names></name>
<name><surname>Ciccone</surname><given-names>G.</given-names></name>
<name><surname>Ricardi</surname><given-names>U.</given-names></name>
<name><surname>Kriachok</surname><given-names>I.</given-names></name>
<name><surname>Botto</surname><given-names>B.</given-names></name>
<name><surname>Balzarotti</surname><given-names>M.</given-names></name>
<name><surname>Tucci</surname><given-names>A.</given-names></name>
<name><surname>Usai</surname><given-names>S.V.</given-names></name>
<name><surname>Zilioli</surname><given-names>V.R.</given-names></name>
<etal/>
</person-group><article-title>Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>4071</fpage><lpage>4083</lpage><pub-id pub-id-type="doi">10.1200/JCO-24-01373</pub-id><pub-id pub-id-type="pmid">39159403</pub-id>
</element-citation></ref><ref id="B90-hematolrep-17-00023"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velasques</surname><given-names>R.D.</given-names></name>
<name><surname>Da Silva</surname><given-names>W.F.</given-names></name>
<name><surname>Bellesso</surname><given-names>M.</given-names></name>
<name><surname>Rocha</surname><given-names>V.</given-names></name>
<name><surname>Pereira</surname><given-names>J.</given-names></name>
</person-group><article-title>Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings</article-title><source>J. Oncol.</source><year>2022</year><volume>2022</volume><fpage>2099456</fpage><pub-id pub-id-type="doi">10.1155/2022/2099456</pub-id><pub-id pub-id-type="pmid">35706929</pub-id>
</element-citation></ref><ref id="B91-hematolrep-17-00023"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunleavy</surname><given-names>K.</given-names></name>
<name><surname>Pittaluga</surname><given-names>S.</given-names></name>
<name><surname>Maeda</surname><given-names>L.S.</given-names></name>
<name><surname>Advani</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>C.C.</given-names></name>
<name><surname>Hessler</surname><given-names>J.</given-names></name>
<name><surname>Steinberg</surname><given-names>S.M.</given-names></name>
<name><surname>Grant</surname><given-names>C.</given-names></name>
<name><surname>Wright</surname><given-names>G.</given-names></name>
<name><surname>Varma</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>1408</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214561</pub-id><pub-id pub-id-type="pmid">23574119</pub-id>
</element-citation></ref><ref id="B92-hematolrep-17-00023"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>N.N.</given-names></name>
<name><surname>Szabo</surname><given-names>A.</given-names></name>
<name><surname>Huntington</surname><given-names>S.F.</given-names></name>
<name><surname>Epperla</surname><given-names>N.</given-names></name>
<name><surname>Reddy</surname><given-names>N.</given-names></name>
<name><surname>Ganguly</surname><given-names>S.</given-names></name>
<name><surname>Vose</surname><given-names>J.</given-names></name>
<name><surname>Obiozor</surname><given-names>C.</given-names></name>
<name><surname>Faruqi</surname><given-names>F.</given-names></name>
<name><surname>Kovach</surname><given-names>A.E.</given-names></name>
<etal/>
</person-group><article-title>R-CHOP versus Dose-Adjusted R-EPOCH in Frontline Management of Primary Mediastinal B-Cell Lymphoma: A Multi-Centre Analysis</article-title><source>Br. J. Haematol.</source><year>2018</year><volume>180</volume><fpage>534</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1111/bjh.15051</pub-id><pub-id pub-id-type="pmid">29265182</pub-id>
</element-citation></ref><ref id="B93-hematolrep-17-00023"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giulino-Roth</surname><given-names>L.</given-names></name>
<name><surname>O&#x02019;Donohue</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Bartlett</surname><given-names>N.L.</given-names></name>
<name><surname>LaCasce</surname><given-names>A.</given-names></name>
<name><surname>Martin-Doyle</surname><given-names>W.</given-names></name>
<name><surname>Barth</surname><given-names>M.J.</given-names></name>
<name><surname>Davies</surname><given-names>K.</given-names></name>
<name><surname>Blum</surname><given-names>K.A.</given-names></name>
<name><surname>Christian</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R</article-title><source>Br. J. Haematol.</source><year>2017</year><volume>179</volume><fpage>739</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1111/bjh.14951</pub-id><pub-id pub-id-type="pmid">29082519</pub-id>
</element-citation></ref><ref id="B94-hematolrep-17-00023"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>H.</given-names></name>
<name><surname>Kapoor</surname><given-names>A.</given-names></name>
<name><surname>Sengar</surname><given-names>M.</given-names></name>
<name><surname>Chanana</surname><given-names>R.</given-names></name>
<name><surname>Menon</surname><given-names>H.</given-names></name>
<name><surname>Sridhar</surname><given-names>E.</given-names></name>
<name><surname>Laskar</surname><given-names>S.</given-names></name>
<name><surname>Agarwal</surname><given-names>A.</given-names></name>
<name><surname>Shastri</surname><given-names>J.</given-names></name>
<name><surname>Khanna</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Treated with Dose Adjusted R-EPOCH Regimen: A Single Centre Experience</article-title><source>Indian. J. Hematol. Blood Transfus.</source><year>2021</year><volume>37</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s12288-020-01372-y</pub-id><pub-id pub-id-type="pmid">34267455</pub-id>
</element-citation></ref><ref id="B95-hematolrep-17-00023"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Broccoli</surname><given-names>A.</given-names></name>
<name><surname>Casadei</surname><given-names>B.</given-names></name>
<name><surname>Stefoni</surname><given-names>V.</given-names></name>
<name><surname>Pellegrini</surname><given-names>C.</given-names></name>
<name><surname>Quirini</surname><given-names>F.</given-names></name>
<name><surname>Tonialini</surname><given-names>L.</given-names></name>
<name><surname>Morigi</surname><given-names>A.</given-names></name>
<name><surname>Marangon</surname><given-names>M.</given-names></name>
<name><surname>Argnani</surname><given-names>L.</given-names></name>
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
</person-group><article-title>The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><elocation-id>276</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3269-6</pub-id><pub-id pub-id-type="pmid">28415982</pub-id>
</element-citation></ref><ref id="B96-hematolrep-17-00023"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Stefoni</surname><given-names>V.</given-names></name>
<name><surname>Finolezzi</surname><given-names>E.</given-names></name>
<name><surname>Brusamolino</surname><given-names>E.</given-names></name>
<name><surname>Cabras</surname><given-names>M.G.</given-names></name>
<name><surname>Chiappella</surname><given-names>A.</given-names></name>
<name><surname>Salvi</surname><given-names>F.</given-names></name>
<name><surname>Rossi</surname><given-names>A.</given-names></name>
<name><surname>Broccoli</surname><given-names>A.</given-names></name>
<name><surname>Martelli</surname><given-names>M.</given-names></name>
</person-group><article-title>Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: A retrospective study</article-title><source>Clin. Lymphoma Myeloma</source><year>2009</year><volume>9</volume><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.3816/CLM.2009.n.074</pub-id><pub-id pub-id-type="pmid">19858058</pub-id>
</element-citation></ref><ref id="B97-hematolrep-17-00023"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayden</surname><given-names>A.R.</given-names></name>
<name><surname>Tonseth</surname><given-names>P.</given-names></name>
<name><surname>Lee</surname><given-names>D.G.</given-names></name>
<name><surname>Villa</surname><given-names>D.</given-names></name>
<name><surname>Gerrie</surname><given-names>A.S.</given-names></name>
<name><surname>Scott</surname><given-names>D.W.</given-names></name>
<name><surname>Freeman</surname><given-names>C.L.</given-names></name>
<name><surname>Slack</surname><given-names>G.W.</given-names></name>
<name><surname>Farinha</surname><given-names>P.</given-names></name>
<name><surname>Skinnider</surname><given-names>B.</given-names></name>
</person-group><article-title>Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: Impact of a PET-adapted approach</article-title><source>Blood</source><year>2020</year><volume>136</volume><fpage>2803</fpage><lpage>2811</lpage><pub-id pub-id-type="doi">10.1182/blood.2019004296</pub-id><pub-id pub-id-type="pmid">32603413</pub-id>
</element-citation></ref><ref id="B98-hematolrep-17-00023"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romejko-Jarosinska</surname><given-names>J.</given-names></name>
<name><surname>Ostrowska</surname><given-names>B.</given-names></name>
<name><surname>Dabrowska-Iwanicka</surname><given-names>A.</given-names></name>
<name><surname>Domanska-Czyz</surname><given-names>K.</given-names></name>
<name><surname>Rymkiewicz</surname><given-names>G.</given-names></name>
<name><surname>Paszkiewicz-Kozik</surname><given-names>E.</given-names></name>
<name><surname>Konecki</surname><given-names>R.</given-names></name>
<name><surname>Borawska</surname><given-names>A.</given-names></name>
<name><surname>Druzd-Sitek</surname><given-names>A.</given-names></name>
<name><surname>Lampka</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>10551</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-14067-3</pub-id><pub-id pub-id-type="pmid">35732790</pub-id>
</element-citation></ref><ref id="B99-hematolrep-17-00023"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dourthe</surname><given-names>M.E.</given-names></name>
<name><surname>Phulpin</surname><given-names>A.</given-names></name>
<name><surname>Auperin</surname><given-names>A.</given-names></name>
<name><surname>Bosq</surname><given-names>J.</given-names></name>
<name><surname>Couec</surname><given-names>M.L.</given-names></name>
<name><surname>Dartigues</surname><given-names>P.</given-names></name>
<name><surname>Ducassou</surname><given-names>S.</given-names></name>
<name><surname>Garnier</surname><given-names>N.</given-names></name>
<name><surname>Haouy</surname><given-names>S.</given-names></name>
<name><surname>Leblanc</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: Results of the French LMB2001 prospective study</article-title><source>Haematologica</source><year>2022</year><volume>107</volume><fpage>2173</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.3324/haematol.2021.280257</pub-id><pub-id pub-id-type="pmid">35236054</pub-id>
</element-citation></ref><ref id="B100-hematolrep-17-00023"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vardhana</surname><given-names>S.</given-names></name>
<name><surname>Hamlin</surname><given-names>P.A.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Zelenetz</surname><given-names>A.</given-names></name>
<name><surname>Sauter</surname><given-names>C.S.</given-names></name>
<name><surname>Matasar</surname><given-names>M.J.</given-names></name>
<name><surname>Ni</surname><given-names>A.</given-names></name>
<name><surname>Yahalom</surname><given-names>J.</given-names></name>
<name><surname>Moskowitz</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant</article-title><source>Biol. Blood Marrow Transplant.</source><year>2018</year><volume>24</volume><fpage>2133</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2018.06.009</pub-id><pub-id pub-id-type="pmid">29909154</pub-id>
</element-citation></ref><ref id="B101-hematolrep-17-00023"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melani</surname><given-names>C.</given-names></name>
<name><surname>Advani</surname><given-names>R.</given-names></name>
<name><surname>Roschewski</surname><given-names>M.</given-names></name>
<name><surname>Walters</surname><given-names>K.M.</given-names></name>
<name><surname>Chen</surname><given-names>C.C.</given-names></name>
<name><surname>Baratto</surname><given-names>L.</given-names></name>
<name><surname>Ahlman</surname><given-names>M.A.</given-names></name>
<name><surname>Miljkovic</surname><given-names>M.D.</given-names></name>
<name><surname>Steinberg</surname><given-names>S.M.</given-names></name>
<name><surname>Lam</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: A paradigm shift in clinical decision making</article-title><source>Haematologica</source><year>2018</year><volume>103</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.3324/haematol.2018.192492</pub-id><pub-id pub-id-type="pmid">29748435</pub-id>
</element-citation></ref><ref id="B102-hematolrep-17-00023"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Santoro</surname><given-names>A.</given-names></name>
<name><surname>Gritti</surname><given-names>G.</given-names></name>
<name><surname>Brice</surname><given-names>P.</given-names></name>
<name><surname>Barr</surname><given-names>P.M.</given-names></name>
<name><surname>Kuruvilla</surname><given-names>J.</given-names></name>
<name><surname>Cunningham</surname><given-names>D.</given-names></name>
<name><surname>Kline</surname><given-names>J.</given-names></name>
<name><surname>Johnson</surname><given-names>N.A.</given-names></name>
<name><surname>Mehta-Shah</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>3081</fpage><lpage>3089</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01492</pub-id><pub-id pub-id-type="pmid">31398081</pub-id>
</element-citation></ref><ref id="B103-hematolrep-17-00023"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yousefirizi</surname><given-names>F.</given-names></name>
<name><surname>Gowdy</surname><given-names>C.</given-names></name>
<name><surname>Klyuzhin</surname><given-names>I.S.</given-names></name>
<name><surname>Sabouri</surname><given-names>M.</given-names></name>
<name><surname>Tonseth</surname><given-names>P.</given-names></name>
<name><surname>Hayden</surname><given-names>A.R.</given-names></name>
<name><surname>Wilson</surname><given-names>D.</given-names></name>
<name><surname>Sehn</surname><given-names>L.H.</given-names></name>
<name><surname>Scott</surname><given-names>D.W.</given-names></name>
<name><surname>Steidl</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma</article-title><source>Cancers</source><year>2024</year><volume>16</volume><elocation-id>1090</elocation-id><pub-id pub-id-type="doi">10.3390/cancers16061090</pub-id><pub-id pub-id-type="pmid">38539425</pub-id>
</element-citation></ref><ref id="B104-hematolrep-17-00023"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kochenderfer</surname><given-names>J.N.</given-names></name>
<name><surname>Dudley</surname><given-names>M.E.</given-names></name>
<name><surname>Kassim</surname><given-names>S.H.</given-names></name>
<name><surname>Somerville</surname><given-names>R.P.</given-names></name>
<name><surname>Carpenter</surname><given-names>R.O.</given-names></name>
<name><surname>Stetler-Stevenson</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>J.C.</given-names></name>
<name><surname>Phan</surname><given-names>G.Q.</given-names></name>
<name><surname>Hughes</surname><given-names>M.S.</given-names></name>
<name><surname>Sherry</surname><given-names>R.M.</given-names></name>
<etal/>
</person-group><article-title>Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>540</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.2025</pub-id></element-citation></ref><ref id="B105-hematolrep-17-00023"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crombie</surname><given-names>J.L.</given-names></name>
<name><surname>Nastoupil</surname><given-names>L.J.</given-names></name>
<name><surname>Redd</surname><given-names>R.</given-names></name>
<name><surname>Tang</surname><given-names>K.</given-names></name>
<name><surname>Shouse</surname><given-names>G.</given-names></name>
<name><surname>Herrera</surname><given-names>A.F.</given-names></name>
<name><surname>Chow</surname><given-names>V.A.</given-names></name>
<name><surname>Shadman</surname><given-names>M.</given-names></name>
<name><surname>Castaneda Puglianini</surname><given-names>O.</given-names></name>
<name><surname>Saucier</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma</article-title><source>Blood Adv.</source><year>2021</year><volume>5</volume><fpage>3563</fpage><lpage>3567</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021004880</pub-id><pub-id pub-id-type="pmid">34474474</pub-id>
</element-citation></ref><ref id="B106-hematolrep-17-00023"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiappella</surname><given-names>A.</given-names></name>
<name><surname>Casadei</surname><given-names>B.</given-names></name>
<name><surname>Chiusolo</surname><given-names>P.</given-names></name>
<name><surname>Di Rocco</surname><given-names>A.</given-names></name>
<name><surname>Ljevar</surname><given-names>S.</given-names></name>
<name><surname>Magni</surname><given-names>M.</given-names></name>
<name><surname>Angelillo</surname><given-names>P.</given-names></name>
<name><surname>Barbui</surname><given-names>A.M.</given-names></name>
<name><surname>Cutini</surname><given-names>I.</given-names></name>
<name><surname>Dodero</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: The Italian CART-SIE study</article-title><source>Leukemia</source><year>2024</year><volume>38</volume><fpage>1107</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1038/s41375-024-02213-x</pub-id><pub-id pub-id-type="pmid">38459167</pub-id>
</element-citation></ref><ref id="B107-hematolrep-17-00023"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schubert</surname><given-names>M.L.</given-names></name>
<name><surname>Bethge</surname><given-names>W.A.</given-names></name>
<name><surname>Ayuk</surname><given-names>F.A.</given-names></name>
<name><surname>von Bonin</surname><given-names>M.</given-names></name>
<name><surname>Vucinic</surname><given-names>V.</given-names></name>
<name><surname>Wagner-Drouet</surname><given-names>E.M.</given-names></name>
<name><surname>Subklewe</surname><given-names>M.</given-names></name>
<name><surname>Baldus</surname><given-names>C.D.</given-names></name>
<name><surname>Glass</surname><given-names>B.</given-names></name>
<name><surname>Marks</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: A GLA/DRST registry study</article-title><source>Blood Adv.</source><year>2023</year><volume>7</volume><fpage>6191</fpage><lpage>6195</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2023011203</pub-id><pub-id pub-id-type="pmid">37603595</pub-id>
</element-citation></ref><ref id="B108-hematolrep-17-00023"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neelapu</surname><given-names>S.S.</given-names></name>
<name><surname>Locke</surname><given-names>F.L.</given-names></name>
<name><surname>Bartlett</surname><given-names>N.L.</given-names></name>
<name><surname>Lekakis</surname><given-names>L.J.</given-names></name>
<name><surname>Miklos</surname><given-names>D.B.</given-names></name>
<name><surname>Jacobson</surname><given-names>C.A.</given-names></name>
<name><surname>Braunschweig</surname><given-names>I.</given-names></name>
<name><surname>Oluwole</surname><given-names>O.O.</given-names></name>
<name><surname>Siddiqi</surname><given-names>T.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2531</fpage><lpage>2544</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707447</pub-id><pub-id pub-id-type="pmid">29226797</pub-id>
</element-citation></ref><ref id="B109-hematolrep-17-00023"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abramson</surname><given-names>J.S.</given-names></name>
<name><surname>Palomba</surname><given-names>M.L.</given-names></name>
<name><surname>Gordon</surname><given-names>L.I.</given-names></name>
<name><surname>Lunning</surname><given-names>M.A.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Arnason</surname><given-names>J.</given-names></name>
<name><surname>Mehta</surname><given-names>A.</given-names></name>
<name><surname>Purev</surname><given-names>E.</given-names></name>
<name><surname>Maloney</surname><given-names>D.G.</given-names></name>
<name><surname>Andreadis</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study</article-title><source>Lancet Lond Engl.</source><year>2020</year><volume>396</volume><fpage>839</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31366-0</pub-id></element-citation></ref><ref id="B110-hematolrep-17-00023"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abramson</surname><given-names>J.S.</given-names></name>
<name><surname>Solomon</surname><given-names>S.R.</given-names></name>
<name><surname>Arnason</surname><given-names>J.</given-names></name>
<name><surname>Johnston</surname><given-names>P.B.</given-names></name>
<name><surname>Glass</surname><given-names>B.</given-names></name>
<name><surname>Bachanova</surname><given-names>V.</given-names></name>
<name><surname>Ibrahimi</surname><given-names>S.</given-names></name>
<name><surname>Mielke</surname><given-names>S.</given-names></name>
<name><surname>Mutsaers</surname><given-names>P.</given-names></name>
<name><surname>Hernandez-Ilizaliturri</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>1675</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1182/blood.2022018730</pub-id><pub-id pub-id-type="pmid">36542826</pub-id>
</element-citation></ref><ref id="B111-hematolrep-17-00023"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Locke</surname><given-names>F.L.</given-names></name>
<name><surname>Miklos</surname><given-names>D.B.</given-names></name>
<name><surname>Jacobson</surname><given-names>C.A.</given-names></name>
<name><surname>Perales</surname><given-names>M.A.</given-names></name>
<name><surname>Kersten</surname><given-names>M.J.</given-names></name>
<name><surname>Oluwole</surname><given-names>O.O.</given-names></name>
<name><surname>Ghobadi</surname><given-names>A.</given-names></name>
<name><surname>Rapoport</surname><given-names>A.P.</given-names></name>
<name><surname>McGuirk</surname><given-names>J.</given-names></name>
<name><surname>Pagel</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>640</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116133</pub-id><pub-id pub-id-type="pmid">34891224</pub-id>
</element-citation></ref><ref id="B112-hematolrep-17-00023"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Armand</surname><given-names>P.</given-names></name>
<name><surname>Rodig</surname><given-names>S.</given-names></name>
<name><surname>Melnichenko</surname><given-names>V.</given-names></name>
<name><surname>Thieblemont</surname><given-names>C.</given-names></name>
<name><surname>Bouabdallah</surname><given-names>K.</given-names></name>
<name><surname>Tumyan</surname><given-names>G.</given-names></name>
<name><surname>&#x000d6;zcan</surname><given-names>M.</given-names></name>
<name><surname>Portino</surname><given-names>S.</given-names></name>
<name><surname>Fogliatto</surname><given-names>L.</given-names></name>
<name><surname>Caballero</surname><given-names>M.D.</given-names></name>
<etal/>
</person-group><article-title>Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>3291</fpage><lpage>3299</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.01389</pub-id><pub-id pub-id-type="pmid">31609651</pub-id>
</element-citation></ref><ref id="B113-hematolrep-17-00023"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zinzani</surname><given-names>P.L.</given-names></name>
<name><surname>Ribrag</surname><given-names>V.</given-names></name>
<name><surname>Moskowitz</surname><given-names>C.H.</given-names></name>
<name><surname>Michot</surname><given-names>J.M.</given-names></name>
<name><surname>Kuruvilla</surname><given-names>J.</given-names></name>
<name><surname>Balakumaran</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Chlosta</surname><given-names>S.</given-names></name>
<name><surname>Shipp</surname><given-names>M.A.</given-names></name>
<name><surname>Armand</surname><given-names>P.</given-names></name>
</person-group><article-title>Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma</article-title><source>Blood.</source><year>2017</year><volume>130</volume><fpage>267</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-12-758383</pub-id><pub-id pub-id-type="pmid">28490569</pub-id>
</element-citation></ref><ref id="B114-hematolrep-17-00023"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Westin</surname><given-names>J.R.</given-names></name>
<name><surname>Oluwole</surname><given-names>O.O.</given-names></name>
<name><surname>Kersten</surname><given-names>M.J.</given-names></name>
<name><surname>Miklos</surname><given-names>D.B.</given-names></name>
<name><surname>Perales</surname><given-names>M.A.</given-names></name>
<name><surname>Ghobadi</surname><given-names>A.</given-names></name>
<name><surname>Rapoport</surname><given-names>A.P.</given-names></name>
<name><surname>Sureda</surname><given-names>A.</given-names></name>
<name><surname>Jacobson</surname><given-names>C.A.</given-names></name>
<name><surname>Farooq</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2301665</pub-id><pub-id pub-id-type="pmid">37272527</pub-id>
</element-citation></ref><ref id="B115-hematolrep-17-00023"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Yoon</surname><given-names>D.H.</given-names></name>
<name><surname>Kang</surname><given-names>H.J.</given-names></name>
<name><surname>Hong</surname><given-names>J.Y.</given-names></name>
<name><surname>Lee</surname><given-names>H.S.</given-names></name>
<name><surname>Oh</surname><given-names>S.Y.</given-names></name>
<name><surname>Shin</surname><given-names>H.J.</given-names></name>
<name><surname>Kong</surname><given-names>J.H.</given-names></name>
<name><surname>Yi</surname><given-names>J.H.</given-names></name>
<name><surname>Sakamoto</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><elocation-id>1080</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-019-6303-z</pub-id><pub-id pub-id-type="pmid">31707975</pub-id>
</element-citation></ref><ref id="B116-hematolrep-17-00023"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dickinson</surname><given-names>M.J.</given-names></name>
<name><surname>Carlo-Stella</surname><given-names>C.</given-names></name>
<name><surname>Morschhauser</surname><given-names>F.</given-names></name>
<name><surname>Bachy</surname><given-names>E.</given-names></name>
<name><surname>Corradini</surname><given-names>P.</given-names></name>
<name><surname>Iacoboni</surname><given-names>G.</given-names></name>
<name><surname>Khan</surname><given-names>C.</given-names></name>
<name><surname>Wr&#x000f3;bel</surname><given-names>T.</given-names></name>
<name><surname>Offner</surname><given-names>F.</given-names></name>
<name><surname>Trn&#x0011b;n&#x000fd;</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>2220</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2206913</pub-id><pub-id pub-id-type="pmid">36507690</pub-id>
</element-citation></ref><ref id="B117-hematolrep-17-00023"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thieblemont</surname><given-names>C.</given-names></name>
<name><surname>Phillips</surname><given-names>T.</given-names></name>
<name><surname>Ghesquieres</surname><given-names>H.</given-names></name>
<name><surname>Cheah</surname><given-names>C.Y.</given-names></name>
<name><surname>Clausen</surname><given-names>M.R.</given-names></name>
<name><surname>Cunningham</surname><given-names>D.</given-names></name>
<name><surname>Do</surname><given-names>Y.R.</given-names></name>
<name><surname>Feldman</surname><given-names>T.</given-names></name>
<name><surname>Gasiorowski</surname><given-names>R.</given-names></name>
<name><surname>Jurczak</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell&#x02013;Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>2238</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01725</pub-id><pub-id pub-id-type="pmid">36548927</pub-id>
</element-citation></ref><ref id="B118-hematolrep-17-00023"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>International Non-Hodgkin&#x02019;s Lymphoma Prognostic Factors Project</collab>
</person-group><article-title>A predictive model for aggressive non-Hodgkin&#x02019;s lymphoma</article-title><source>N. Engl. J. Med.</source><year>1993</year><volume>329</volume><fpage>987</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1056/NEJM199309303291402</pub-id><pub-id pub-id-type="pmid">8141877</pub-id>
</element-citation></ref><ref id="B119-hematolrep-17-00023"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albano</surname><given-names>D.</given-names></name>
<name><surname>Dondi</surname><given-names>F.</given-names></name>
<name><surname>Mazzoletti</surname><given-names>A.</given-names></name>
<name><surname>Bellini</surname><given-names>P.</given-names></name>
<name><surname>Giubbini</surname><given-names>R.</given-names></name>
<name><surname>Bertagna</surname><given-names>F.</given-names></name>
</person-group><article-title>Prognostic Impact of Pretreatment 2-[18F]-FDG PET/CT Parameters in Primary Gastric DLBCL</article-title><source>Medicina</source><year>2021</year><volume>57</volume><elocation-id>498</elocation-id><pub-id pub-id-type="doi">10.3390/medicina57050498</pub-id><pub-id pub-id-type="pmid">34069203</pub-id>
</element-citation></ref><ref id="B120-hematolrep-17-00023"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albano</surname><given-names>D.</given-names></name>
<name><surname>Pasinetti</surname><given-names>N.</given-names></name>
<name><surname>Dondi</surname><given-names>F.</given-names></name>
<name><surname>Giubbini</surname><given-names>R.</given-names></name>
<name><surname>Tucci</surname><given-names>A.</given-names></name>
<name><surname>Bertagna</surname><given-names>F.</given-names></name>
</person-group><article-title>Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>1210</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11051210</pub-id><pub-id pub-id-type="pmid">35268301</pub-id>
</element-citation></ref><ref id="B121-hematolrep-17-00023"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheson</surname><given-names>B.D.</given-names></name>
</person-group><article-title>Staging and response assessment in lymphomas: The new Lugano classification</article-title><source>Chin. Clin. Oncol.</source><year>2015</year><volume>4</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.3978/j.issn.2304-3865.2014.11.03</pub-id><pub-id pub-id-type="pmid">25841712</pub-id>
</element-citation></ref><ref id="B122-hematolrep-17-00023"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miceli</surname><given-names>A.</given-names></name>
<name><surname>Jonghi-Lavarini</surname><given-names>L.</given-names></name>
<name><surname>Santo</surname><given-names>G.</given-names></name>
<name><surname>Cassarino</surname><given-names>G.</given-names></name>
<name><surname>Linguanti</surname><given-names>F.</given-names></name>
<name><surname>Gazzilli</surname><given-names>M.</given-names></name>
<name><surname>Cimino</surname><given-names>A.</given-names></name>
<name><surname>Buschiazzo</surname><given-names>A.</given-names></name>
<name><surname>Sorbello</surname><given-names>S.</given-names></name>
<name><surname>Abenavoli</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond</article-title><source>Clin. Transl. Imaging</source><year>2023</year><volume>11</volume><fpage>421</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s40336-023-00578-0</pub-id></element-citation></ref><ref id="B123-hematolrep-17-00023"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pang</surname><given-names>D.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Teng</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
</person-group><article-title>Ctdna Monitoring in Predicting Relapse of Primary Mediastinal BCell Lymphoma</article-title><source>Blood</source><year>2020</year><volume>136</volume><issue>(Suppl. S1)</issue><fpage>36</fpage><pub-id pub-id-type="doi">10.1182/blood-2020-142349</pub-id><pub-id pub-id-type="pmid">32430502</pub-id>
</element-citation></ref><ref id="B124-hematolrep-17-00023"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jmenez-Ubieto</surname><given-names>A.</given-names></name>
<name><surname>Poza</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;n-Mu&#x000f1;oz</surname><given-names>A.</given-names></name>
<name><surname>Dorado</surname><given-names>S.</given-names></name>
<name><surname>Heredia</surname><given-names>Y.</given-names></name>
<name><surname>Sarandeses</surname><given-names>P.</given-names></name>
<name><surname>B&#x000e1;rcena</surname><given-names>C.</given-names></name>
<name><surname>Rufian</surname><given-names>L.</given-names></name>
<name><surname>Canales</surname><given-names>M.</given-names></name>
<name><surname>Juarez</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH</article-title><source>Blood</source><year>2021</year><volume>138</volume><issue>(Suppl. S1)</issue><fpage>4491</fpage><pub-id pub-id-type="doi">10.1182/blood-2021-152376</pub-id></element-citation></ref><ref id="B125-hematolrep-17-00023"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>P.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Ou</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Circulating tumor DNA assisting lymphoma genetic feature profiling and identification</article-title><source>Ann. Hematol.</source><year>2024</year><volume>103</volume><fpage>4135</fpage><lpage>4144</lpage><pub-id pub-id-type="doi">10.1007/s00277-024-05782-0</pub-id><pub-id pub-id-type="pmid">39012515</pub-id>
</element-citation></ref><ref id="B126-hematolrep-17-00023"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhalla</surname><given-names>D.</given-names></name>
<name><surname>Jana</surname><given-names>M.</given-names></name>
<name><surname>Kandasamy</surname><given-names>D.</given-names></name>
</person-group><article-title>Diagnostic accuracy of whole-body magnetic resonance imaging versus positron emission tomography-computed tomography for the staging of pediatric lymphoma: A systematic review and meta-analysis</article-title><source>Pediatr. Radiol.</source><year>2023</year><volume>53</volume><fpage>2683</fpage><lpage>2691</lpage><pub-id pub-id-type="doi">10.1007/s00247-023-05775-7</pub-id><pub-id pub-id-type="pmid">37814104</pub-id>
</element-citation></ref><ref id="B127-hematolrep-17-00023"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albano</surname><given-names>D.</given-names></name>
<name><surname>Dondi</surname><given-names>F.</given-names></name>
<name><surname>Bertagna</surname><given-names>F.</given-names></name>
<name><surname>Treglia</surname><given-names>G.</given-names></name>
</person-group><article-title>The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>3814</elocation-id><!--<pub-id pub-id-type="pmcid">PMC9367619</pub-id>--><pub-id pub-id-type="doi">10.3390/cancers14153814</pub-id><pub-id pub-id-type="pmid">35954476</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="hematolrep-17-00023-t001"><object-id pub-id-type="pii">hematolrep-17-00023-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of included studies on [18F]FDG PET/CT at diagnosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N. Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PET Parameters and Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhu et al. [<xref rid="B35-hematolrep-17-00023" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">136 (65 TET and 71 PMBCL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with lymphoma were younger and had higher SUVmean, SUVmax, TLG, and MTV values than patients with TETs.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yan et al. [<xref rid="B36-hematolrep-17-00023" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">304 (60 with lymphoma, 244 with TET)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoma was significantly associated with younger patient age, higher LDH level, larger tumor size, and higher SUVmax compared to TETs (<italic toggle="yes">p</italic> &#x0003c; 0.001).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alkhawtani et al. [<xref rid="B37-hematolrep-17-00023" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56 (42 with mediastinal HL and 14 with PMBCL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lesion-to-liver SUVmax ratio and lesion-to-liver SUVpeak ratio were significantly higher (<italic toggle="yes">p</italic> &#x0003c; 0.001) in PMBCL than in HL. Larger tumor size and more frequent necrosis may help discriminate PMLBCL from HL (<italic toggle="yes">p</italic> = 0.001).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abenavoli et al. [<xref rid="B38-hematolrep-17-00023" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117 patients (80 HL, 29 PMBCL, 8 GZL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax, SUVmean, SUVpeak, MTV, TLG, and texture analysis were measured or performed. SUVmax and TLG were significantly higher in PMBCL, intermediate in GZL, and lowest in HL. MTV was significantly higher in PMBCL and GZL compared to HL. Higher values of heterogeneity and entropy were detected in PMBCL. Zone-Length Non-Uniformity showed higher values in PMBCL.</td></tr></tbody></table><table-wrap-foot><fn><p>Acronyms: TET, thymic epithelial tumor; HL, Hodgkin lymphoma; PMBCL, primary mediastinal B-cell lymphoma; LDH, Lactate dehydrogenase (LDH); SUVmax, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; l; GZL, gray zone lymphoma.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="hematolrep-17-00023-t002"><object-id pub-id-type="pii">hematolrep-17-00023-t002_Table 2</object-id><label>Table 2</label><caption><p>Characteristics of included studies on [18F]FDG PET/CT at staging.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N. Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PET Parameters and Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ceriani et al. [<xref rid="B40-hematolrep-17-00023" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103 PMBCL patients (IELSG-26 study)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP or R-CHOP-like RE-VACOP-B or R-MACOP-B; consolidation mediastinal RT (93 patients)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax, TLG, and MTV were included. Elevated MTV and TLG were significantly associated with worse PFS and OS, but not SUVmax.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liu et al. [<xref rid="B42-hematolrep-17-00023" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 PMBCL patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-EPOCH (11 patients) and Radiotherapy (17 patients)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax, SUVmean, MTV, TLG. MTV &#x02265; 500, and TGL &#x02265; 2500 were correlated with worse PFS (<italic toggle="yes">p</italic> = 0.002<break/>and <italic toggle="yes">p</italic> = 0.023, respectively).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhou et al. [<xref rid="B43-hematolrep-17-00023" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166 PMBCL patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, R-EPOCH, R-HCVAD, RT (85 patients), SCT (31 patients)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax &#x0003e; 11.6 was associated with poor prognosis.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pinnix et al. [<xref rid="B24-hematolrep-17-00023" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65 PMBCL patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DA-R-EPOCH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmax, SUVmean, MTV, TLG. MTV, and TLG were powerful prognosticators in predicting progression.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ceriani et al. [<xref rid="B45-hematolrep-17-00023" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103 PMBCL patients (IELSG-26 study)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, R-CHOP-like, R-VACOP-B, R-MACOP-B, RT (93 patients)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUVmean, SUVmax, MTV, TLG, and MH. MH and other parameters did not show any significant relationship. The AUC cut-off of 0.45 was optimal to discriminate patients with disease progression. PFS was longer for patients with low MH (<italic toggle="yes">p</italic> &#x0003c; 0.0001). Elevated MH and elevated TLG were independent prognosticators for PFS, so they were combined in a prognostic model for PFS: patients with both high TLG and high MH had poorer outcomes (<italic toggle="yes">p</italic> &#x0003c; 0.001).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ceriani et al. [<xref rid="B50-hematolrep-17-00023" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103 PMBCL patients (IELSG-26 study)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not applicable</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comparison was made between methods for MTV segmentation by applying three thresholds (FT25%, FT41%, and FT2.5) and a region growing (RG) algorithm. FT25% provided the most accurate estimation of the actual volume. Patients with low MTV had significantly longer PFS and OS, regardless of the method used. The four methods predicted disease progression with similar NPV (95&#x02013;98%), but the highest PPV (45%) was for FT25%, which provided the best model to identify patients with the worst outcome.</td></tr></tbody></table><table-wrap-foot><fn><p>Acronyms: IELSG-26, International Extranodal Lymphoma Study Group; PMBCL, primary mediastinal large B-cell lymphoma; SUVmax, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; PFS, progression free survival; OS, overall survival; MH, metabolic heterogeneity.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="hematolrep-17-00023-t003"><object-id pub-id-type="pii">hematolrep-17-00023-t003_Table 3</object-id><label>Table 3</label><caption><p>Characteristics of included studies about interim [18F]FDG PET/CT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N. Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Timing iPET</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PET Parameters and Findings</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avigdor et al. [<xref rid="B63-hematolrep-17-00023" ref-type="bibr">63</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92 PMBCL patients, of which 30 had iPET</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iPET: before starting the seventh cycle of R-VACOP-B or after the third cycle of R-CHOP21</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-VACOP-B, R-CHOP21</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis. Mid-PET uptake was used to identify different PFSs; however, they had relatively low PPVs.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lazarovici et al. [<xref rid="B62-hematolrep-17-00023" ref-type="bibr">62</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 PMBCL patients</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iPET: after the fourth cycle of immunochemotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-CD20 monoclonal antibody with CHOP or CHOP-like chemotherapy, dose-dense ACVBP, ASCT (nine patients), RT (seven patients)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis, DS, and SUVmax were performed or measured. iPET false positive results were found in 94.1% of cases with a PPV of 16.6%, regardless of using visual analysis, SUVmax, or DS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Qin et al. [<xref rid="B64-hematolrep-17-00023" ref-type="bibr">64</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 PMBCL patients</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iPET: 3 weeks after three cycles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP (22 patients), DA-EPOCH-R (27 patients), RT (14 patients)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For DS, iPET was useful in identifying PMBCL patients with poor clinical outcomes, based on the high PPV of interim DS 5, which should be a candidate for further treatment.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cheah et al. [<xref rid="B34-hematolrep-17-00023" ref-type="bibr">34</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 PMBCL patients, of which 23 ha iPET</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iPET: 8 patients after two cycles, 13 patients after three cycles, and 2 patients after four cycles of chemotherapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-CHOP, DA-EPOCH-R, Hyper-CVAD &#x000b1; R, RT s</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual analysis and DS (DS &#x02265; 4 considered positive) were used. High NPV (87&#x02013;88%) of iPET was detected, while positive iPET was not predictive of inferior PFS, confirming the low PPV for relapse (12.5&#x02013;15%).</td></tr></tbody></table><table-wrap-foot><fn><p>Acronyms: PMBCL, primary mediastinal B-cell lymphoma; iPET, interim PET; SUVmax, maximum standardized uptake value; DS, Deauville score.</p></fn></table-wrap-foot></table-wrap></floats-group></article>